JP6280546B2 - ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法 - Google Patents
ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法 Download PDFInfo
- Publication number
- JP6280546B2 JP6280546B2 JP2015520365A JP2015520365A JP6280546B2 JP 6280546 B2 JP6280546 B2 JP 6280546B2 JP 2015520365 A JP2015520365 A JP 2015520365A JP 2015520365 A JP2015520365 A JP 2015520365A JP 6280546 B2 JP6280546 B2 JP 6280546B2
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- phenyl
- kinase
- group
- tki
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title claims description 219
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title claims description 218
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 title claims description 202
- 206010028980 Neoplasm Diseases 0.000 title claims description 169
- 230000036210 malignancy Effects 0.000 title claims description 109
- 230000035772 mutation Effects 0.000 title claims description 78
- AAFJXZWCNVJTMK-GUCUJZIJSA-N (1s,2r)-1-[(2s)-oxiran-2-yl]-2-[(2r)-oxiran-2-yl]ethane-1,2-diol Chemical compound C([C@@H]1[C@H](O)[C@H](O)[C@H]2OC2)O1 AAFJXZWCNVJTMK-GUCUJZIJSA-N 0.000 title claims description 58
- 101000833492 Homo sapiens Jouberin Proteins 0.000 title claims description 54
- 102100024407 Jouberin Human genes 0.000 title claims description 53
- 229950000758 dianhydrogalactitol Drugs 0.000 title claims description 43
- MMAXAFOTGLVFQZ-UHFFFAOYSA-N [2-acetyloxy-1,2-bis(oxiran-2-yl)ethyl] acetate Chemical compound C1OC1C(OC(=O)C)C(OC(C)=O)C1CO1 MMAXAFOTGLVFQZ-UHFFFAOYSA-N 0.000 title claims description 35
- 230000008482 dysregulation Effects 0.000 title claims description 20
- 206010071602 Genetic polymorphism Diseases 0.000 title description 9
- 210000004027 cell Anatomy 0.000 claims description 175
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 claims description 133
- 239000003112 inhibitor Substances 0.000 claims description 118
- 239000003814 drug Substances 0.000 claims description 115
- 108090000623 proteins and genes Proteins 0.000 claims description 112
- -1 6-Bromopyridin-2-yl Chemical group 0.000 claims description 101
- 201000011510 cancer Diseases 0.000 claims description 97
- 230000014509 gene expression Effects 0.000 claims description 92
- 230000037430 deletion Effects 0.000 claims description 91
- 238000012217 deletion Methods 0.000 claims description 91
- 230000000694 effects Effects 0.000 claims description 89
- 238000000034 method Methods 0.000 claims description 89
- 238000011282 treatment Methods 0.000 claims description 74
- 102000004169 proteins and genes Human genes 0.000 claims description 68
- 239000000126 substance Substances 0.000 claims description 64
- 235000018102 proteins Nutrition 0.000 claims description 63
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 61
- 229940079593 drug Drugs 0.000 claims description 59
- 230000001225 therapeutic effect Effects 0.000 claims description 59
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 55
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 55
- 108010040168 Bcl-2-Like Protein 11 Proteins 0.000 claims description 54
- 102000001765 Bcl-2-Like Protein 11 Human genes 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 50
- 150000001875 compounds Chemical class 0.000 claims description 46
- 239000003795 chemical substances by application Substances 0.000 claims description 42
- 210000004602 germ cell Anatomy 0.000 claims description 41
- 230000006872 improvement Effects 0.000 claims description 41
- 102000001301 EGF receptor Human genes 0.000 claims description 38
- 108060006698 EGF receptor Proteins 0.000 claims description 38
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 36
- 230000006907 apoptotic process Effects 0.000 claims description 34
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 34
- 229960002411 imatinib Drugs 0.000 claims description 34
- 229940124597 therapeutic agent Drugs 0.000 claims description 34
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 33
- 108010029477 STAT5 Transcription Factor Proteins 0.000 claims description 32
- 230000001965 increasing effect Effects 0.000 claims description 32
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 31
- 101150038313 AHI1 gene Proteins 0.000 claims description 29
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 claims description 27
- 229940043355 kinase inhibitor Drugs 0.000 claims description 27
- 108010029485 Protein Isoforms Proteins 0.000 claims description 25
- 102000001708 Protein Isoforms Human genes 0.000 claims description 25
- 230000027455 binding Effects 0.000 claims description 23
- 230000002829 reductive effect Effects 0.000 claims description 23
- 108060006633 protein kinase Proteins 0.000 claims description 22
- 102000001253 Protein Kinase Human genes 0.000 claims description 21
- 238000009739 binding Methods 0.000 claims description 21
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 20
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 claims description 19
- 108091000080 Phosphotransferase Proteins 0.000 claims description 19
- 239000000562 conjugate Substances 0.000 claims description 19
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 claims description 19
- 102000020233 phosphotransferase Human genes 0.000 claims description 19
- 229940122924 Src inhibitor Drugs 0.000 claims description 18
- 150000002148 esters Chemical class 0.000 claims description 17
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 claims description 17
- 230000004913 activation Effects 0.000 claims description 16
- 230000008859 change Effects 0.000 claims description 15
- 238000003780 insertion Methods 0.000 claims description 15
- 230000037431 insertion Effects 0.000 claims description 15
- 229950004847 navitoclax Drugs 0.000 claims description 14
- 230000011664 signaling Effects 0.000 claims description 14
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 13
- 108020004414 DNA Proteins 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 13
- 230000003993 interaction Effects 0.000 claims description 13
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 claims description 12
- 229940100198 alkylating agent Drugs 0.000 claims description 12
- 239000002168 alkylating agent Substances 0.000 claims description 12
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 12
- 230000001566 pro-viral effect Effects 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 12
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 11
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 11
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 11
- PQAPVTKIEGUPRN-UHFFFAOYSA-N N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide Chemical compound CC(C)C1=CC=CC=C1CC1=CC(C(=O)NC=2C=CC(=CC=2)S(=O)(=O)C=2C(=CC=CC=2)C(C)(C)C)=C(O)C(O)=C1O PQAPVTKIEGUPRN-UHFFFAOYSA-N 0.000 claims description 11
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 claims description 11
- 235000001014 amino acid Nutrition 0.000 claims description 11
- 229960002448 dasatinib Drugs 0.000 claims description 11
- DWEHITNKTMMZBR-RUZDIDTESA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-(4,4-dimethylpiperidin-1-yl)benzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCC(C)(C)CC1)[N+]([O-])=O)SC1=CC=CC=C1 DWEHITNKTMMZBR-RUZDIDTESA-N 0.000 claims description 11
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 claims description 10
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 claims description 10
- 229960001948 caffeine Drugs 0.000 claims description 10
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 10
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 10
- 230000019491 signal transduction Effects 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 10
- 230000002152 alkylating effect Effects 0.000 claims description 9
- 230000037361 pathway Effects 0.000 claims description 9
- 102000005962 receptors Human genes 0.000 claims description 9
- 108020003175 receptors Proteins 0.000 claims description 9
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims description 8
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims description 8
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims description 8
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 8
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 claims description 8
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims description 8
- 229940093265 berberine Drugs 0.000 claims description 8
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims description 8
- 125000002619 bicyclic group Chemical group 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 8
- 230000002209 hydrophobic effect Effects 0.000 claims description 8
- 230000006882 induction of apoptosis Effects 0.000 claims description 8
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 7
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 claims description 7
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 7
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 7
- 238000012377 drug delivery Methods 0.000 claims description 7
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 claims description 7
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 7
- 229960001346 nilotinib Drugs 0.000 claims description 7
- 239000000816 peptidomimetic Substances 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 6
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims description 6
- HRYILSDLIGTCOP-UHFFFAOYSA-N N-benzoylurea Chemical compound NC(=O)NC(=O)C1=CC=CC=C1 HRYILSDLIGTCOP-UHFFFAOYSA-N 0.000 claims description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 6
- 230000029936 alkylation Effects 0.000 claims description 6
- 238000005804 alkylation reaction Methods 0.000 claims description 6
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims description 6
- 229940117893 apigenin Drugs 0.000 claims description 6
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims description 6
- 235000008714 apigenin Nutrition 0.000 claims description 6
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims description 6
- 229960003736 bosutinib Drugs 0.000 claims description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 6
- 229960004316 cisplatin Drugs 0.000 claims description 6
- 229940109262 curcumin Drugs 0.000 claims description 6
- 235000012754 curcumin Nutrition 0.000 claims description 6
- 239000004148 curcumin Substances 0.000 claims description 6
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 229960002949 fluorouracil Drugs 0.000 claims description 6
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 6
- 108091005601 modified peptides Proteins 0.000 claims description 6
- 230000036457 multidrug resistance Effects 0.000 claims description 6
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 claims description 6
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims description 6
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 claims description 6
- TUCIOBMMDDOEMM-RIYZIHGNSA-N tyrphostin B42 Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCC1=CC=CC=C1 TUCIOBMMDDOEMM-RIYZIHGNSA-N 0.000 claims description 6
- JFJNVIPVOCESGZ-UHFFFAOYSA-N 2,3-dipyridin-2-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CN=C1C1=CC=CC=N1 JFJNVIPVOCESGZ-UHFFFAOYSA-N 0.000 claims description 5
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 claims description 5
- 101150092671 BIM gene Proteins 0.000 claims description 5
- 229920000858 Cyclodextrin Polymers 0.000 claims description 5
- 206010070834 Sensitisation Diseases 0.000 claims description 5
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 5
- 230000000340 anti-metabolite Effects 0.000 claims description 5
- 229940100197 antimetabolite Drugs 0.000 claims description 5
- 239000002256 antimetabolite Substances 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 5
- 230000002068 genetic effect Effects 0.000 claims description 5
- 229940045109 genistein Drugs 0.000 claims description 5
- 235000006539 genistein Nutrition 0.000 claims description 5
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 5
- 229960003539 mitoguazone Drugs 0.000 claims description 5
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 5
- 230000008439 repair process Effects 0.000 claims description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 5
- 230000008313 sensitization Effects 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 5
- MHSKRLJMQQNJNC-UHFFFAOYSA-N terephthalamide Chemical compound NC(=O)C1=CC=C(C(N)=O)C=C1 MHSKRLJMQQNJNC-UHFFFAOYSA-N 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- UPALIKSFLSVKIS-UHFFFAOYSA-N 5-amino-2-[2-(dimethylamino)ethyl]benzo[de]isoquinoline-1,3-dione Chemical compound NC1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 UPALIKSFLSVKIS-UHFFFAOYSA-N 0.000 claims description 4
- PDOQBOJDRPLBQU-QMMMGPOBSA-N 5-chloro-2-n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1N=CC(F)=CN=1)C(N=1)=NC=C(Cl)C=1NC=1C=C(C)NN=1 PDOQBOJDRPLBQU-QMMMGPOBSA-N 0.000 claims description 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- SQSZANZGUXWJEA-UHFFFAOYSA-N Gandotinib Chemical compound N1C(C)=CC(NC2=NN3C(CC=4C(=CC(Cl)=CC=4)F)=C(C)N=C3C(CN3CCOCC3)=C2)=N1 SQSZANZGUXWJEA-UHFFFAOYSA-N 0.000 claims description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- 101000634975 Homo sapiens Tripartite motif-containing protein 29 Proteins 0.000 claims description 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 claims description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 4
- 108091007960 PI3Ks Proteins 0.000 claims description 4
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 4
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims description 4
- 229920000954 Polyglycolide Polymers 0.000 claims description 4
- JVDOKQYTTYUYDV-UHFFFAOYSA-N TG101209 Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(C)C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)=N1 JVDOKQYTTYUYDV-UHFFFAOYSA-N 0.000 claims description 4
- 229960004701 amonafide Drugs 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229920002988 biodegradable polymer Polymers 0.000 claims description 4
- 239000004621 biodegradable polymer Substances 0.000 claims description 4
- 229960000684 cytarabine Drugs 0.000 claims description 4
- 229960001433 erlotinib Drugs 0.000 claims description 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 4
- 229960005420 etoposide Drugs 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- RFZKSQIFOZZIAQ-UHFFFAOYSA-N n-[3-(4-methylpiperazin-1-yl)phenyl]-8-(4-methylsulfonylphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine Chemical compound C1CN(C)CCN1C1=CC=CC(NC2=NN3C=CC=C(C3=N2)C=2C=CC(=CC=2)S(C)(=O)=O)=C1 RFZKSQIFOZZIAQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002777 nucleoside Substances 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 230000036961 partial effect Effects 0.000 claims description 4
- NDTYTMIUWGWIMO-UHFFFAOYSA-N perillyl alcohol Chemical compound CC(=C)C1CCC(CO)=CC1 NDTYTMIUWGWIMO-UHFFFAOYSA-N 0.000 claims description 4
- 108010056274 polo-like kinase 1 Proteins 0.000 claims description 4
- 229960003581 pyridoxal Drugs 0.000 claims description 4
- 235000008164 pyridoxal Nutrition 0.000 claims description 4
- 239000011674 pyridoxal Substances 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims description 4
- 239000003734 thymidylate synthase inhibitor Substances 0.000 claims description 4
- HUNGUWOZPQBXGX-UHFFFAOYSA-N tirbanibulin Chemical compound C=1C=CC=CC=1CNC(=O)CC(N=C1)=CC=C1C(C=C1)=CC=C1OCCN1CCOCC1 HUNGUWOZPQBXGX-UHFFFAOYSA-N 0.000 claims description 4
- ISOCDPQFIXDIMS-QHCPKHFHSA-N (2s)-n-[4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]phenyl]pyrrolidine-2-carboxamide Chemical compound O=C([C@H]1NCCC1)NC(C=C1)=CC=C1C(N=1)=CC=NC=1NC(C=C1)=CC=C1N1CCOCC1 ISOCDPQFIXDIMS-QHCPKHFHSA-N 0.000 claims description 3
- VFUAJMPDXIRPKO-LQELWAHVSA-N (e)-3-(6-bromopyridin-2-yl)-2-cyano-n-[(1s)-1-phenylethyl]prop-2-enamide Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)C(\C#N)=C\C1=CC=CC(Br)=N1 VFUAJMPDXIRPKO-LQELWAHVSA-N 0.000 claims description 3
- ZCCPLJOKGAACRT-UHFFFAOYSA-N 4-methyl-3-[[1-methyl-6-(3-pyridinyl)-4-pyrazolo[3,4-d]pyrimidinyl]amino]-N-[3-(trifluoromethyl)phenyl]benzamide Chemical compound CC1=CC=C(C(=O)NC=2C=C(C=CC=2)C(F)(F)F)C=C1NC(C=1C=NN(C)C=1N=1)=NC=1C1=CC=CN=C1 ZCCPLJOKGAACRT-UHFFFAOYSA-N 0.000 claims description 3
- SUNXHXDJOIXABJ-NSHDSACASA-N 5-fluoro-2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 SUNXHXDJOIXABJ-NSHDSACASA-N 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 3
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims description 3
- 206010059866 Drug resistance Diseases 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 102000042838 JAK family Human genes 0.000 claims description 3
- 108091082332 JAK family Proteins 0.000 claims description 3
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims description 3
- 239000002262 Schiff base Substances 0.000 claims description 3
- 150000004753 Schiff bases Chemical class 0.000 claims description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 3
- 229940123237 Taxane Drugs 0.000 claims description 3
- 229940122149 Thymidylate synthase inhibitor Drugs 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims description 3
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 3
- 229960001686 afatinib Drugs 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 229940022399 cancer vaccine Drugs 0.000 claims description 3
- 238000009566 cancer vaccine Methods 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000003431 cross linking reagent Substances 0.000 claims description 3
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 claims description 3
- 229950002205 dacomitinib Drugs 0.000 claims description 3
- 239000000539 dimer Substances 0.000 claims description 3
- 229960005102 foscarnet Drugs 0.000 claims description 3
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 claims description 3
- 239000004005 microsphere Substances 0.000 claims description 3
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 claims description 3
- 239000002159 nanocrystal Substances 0.000 claims description 3
- 239000011570 nicotinamide Substances 0.000 claims description 3
- 229960003966 nicotinamide Drugs 0.000 claims description 3
- 235000005152 nicotinamide Nutrition 0.000 claims description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims description 3
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 3
- 229930007631 (-)-perillyl alcohol Natural products 0.000 claims description 2
- BNZPFJBUHRBLNB-UHFFFAOYSA-N 1-oxido-1,2,4-benzotriazin-1-ium Chemical compound C1=CC=C2[N+]([O-])=NC=NC2=C1 BNZPFJBUHRBLNB-UHFFFAOYSA-N 0.000 claims description 2
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 2
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 claims description 2
- IBPVXAOOVUAOKJ-UHFFFAOYSA-N 4-[[2,6-difluoro-4-[3-(1-piperidin-4-ylpyrazol-4-yl)quinoxalin-5-yl]phenyl]methyl]morpholine Chemical compound FC1=CC(C=2C3=NC(=CN=C3C=CC=2)C2=CN(N=C2)C2CCNCC2)=CC(F)=C1CN1CCOCC1 IBPVXAOOVUAOKJ-UHFFFAOYSA-N 0.000 claims description 2
- 229940121683 Acetylcholine receptor antagonist Drugs 0.000 claims description 2
- 102000006772 Acid Ceramidase Human genes 0.000 claims description 2
- 108020005296 Acid Ceramidase Proteins 0.000 claims description 2
- 229940123786 Adenosine A3 receptor antagonist Drugs 0.000 claims description 2
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 108091007065 BIRCs Proteins 0.000 claims description 2
- 108091007914 CDKs Proteins 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 102000014914 Carrier Proteins Human genes 0.000 claims description 2
- 101710095468 Cyclase Proteins 0.000 claims description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims description 2
- 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 claims description 2
- 229940122280 Cytochrome P450 inhibitor Drugs 0.000 claims description 2
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 claims description 2
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 claims description 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims description 2
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims description 2
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 claims description 2
- 229940122601 Esterase inhibitor Drugs 0.000 claims description 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims description 2
- 102000005720 Glutathione transferase Human genes 0.000 claims description 2
- 108010070675 Glutathione transferase Proteins 0.000 claims description 2
- 101710113864 Heat shock protein 90 Proteins 0.000 claims description 2
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims description 2
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 claims description 2
- 101710184069 Hepatocyte growth factor receptor Proteins 0.000 claims description 2
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 claims description 2
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 claims description 2
- 101000785063 Homo sapiens Serine-protein kinase ATM Proteins 0.000 claims description 2
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 claims description 2
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 claims description 2
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims description 2
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 claims description 2
- 108060006687 MAP kinase kinase kinase Proteins 0.000 claims description 2
- 102000002151 Microfilament Proteins Human genes 0.000 claims description 2
- 108010040897 Microfilament Proteins Proteins 0.000 claims description 2
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims description 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims description 2
- 101150056950 Ntrk2 gene Proteins 0.000 claims description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims description 2
- 108010038807 Oligopeptides Proteins 0.000 claims description 2
- 102000015636 Oligopeptides Human genes 0.000 claims description 2
- 239000012661 PARP inhibitor Substances 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 2
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 2
- 108091008611 Protein Kinase B Proteins 0.000 claims description 2
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 claims description 2
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 claims description 2
- 108020005115 Pyruvate Kinase Proteins 0.000 claims description 2
- 102000013009 Pyruvate Kinase Human genes 0.000 claims description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims description 2
- 108091005682 Receptor kinases Proteins 0.000 claims description 2
- 108010083644 Ribonucleases Proteins 0.000 claims description 2
- 102000006382 Ribonucleases Human genes 0.000 claims description 2
- 101150099493 STAT3 gene Proteins 0.000 claims description 2
- 102100020824 Serine-protein kinase ATM Human genes 0.000 claims description 2
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims description 2
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 claims description 2
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims description 2
- 241000710960 Sindbis virus Species 0.000 claims description 2
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 claims description 2
- 108010022394 Threonine synthase Proteins 0.000 claims description 2
- 239000004012 Tofacitinib Substances 0.000 claims description 2
- 102100029519 Tripartite motif-containing protein 29 Human genes 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 claims description 2
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 claims description 2
- 239000002580 adenosine A3 receptor antagonist Substances 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 239000005441 aurora Substances 0.000 claims description 2
- 229940049706 benzodiazepine Drugs 0.000 claims description 2
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 2
- 108091008324 binding proteins Proteins 0.000 claims description 2
- 229930003827 cannabinoid Natural products 0.000 claims description 2
- 239000003557 cannabinoid Substances 0.000 claims description 2
- 229940065144 cannabinoids Drugs 0.000 claims description 2
- 229960001380 cimetidine Drugs 0.000 claims description 2
- 230000003081 coactivator Effects 0.000 claims description 2
- 229940111134 coxibs Drugs 0.000 claims description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims description 2
- 238000002651 drug therapy Methods 0.000 claims description 2
- 230000001973 epigenetic effect Effects 0.000 claims description 2
- 239000002329 esterase inhibitor Substances 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 229950008908 gandotinib Drugs 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 2
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 claims description 2
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims description 2
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 2
- 150000002678 macrocyclic compounds Chemical class 0.000 claims description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 2
- DAVIKTBRCQWOGT-GIJQJNRQSA-N n-[(e)-(4-oxochromen-3-yl)methylideneamino]pyridine-3-carboxamide Chemical group C=1OC2=CC=CC=C2C(=O)C=1/C=N/NC(=O)C1=CC=CN=C1 DAVIKTBRCQWOGT-GIJQJNRQSA-N 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 108020004017 nuclear receptors Proteins 0.000 claims description 2
- 230000005937 nuclear translocation Effects 0.000 claims description 2
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 claims description 2
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 229950011410 pacritinib Drugs 0.000 claims description 2
- HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 claims description 2
- 235000005693 perillyl alcohol Nutrition 0.000 claims description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims description 2
- 229960003243 phenformin Drugs 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 2
- 150000008299 phosphorodiamidates Chemical class 0.000 claims description 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims description 2
- 229960003634 pimozide Drugs 0.000 claims description 2
- 239000000580 polymer-drug conjugate Substances 0.000 claims description 2
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims description 2
- 239000003909 protein kinase inhibitor Substances 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 239000003590 rho kinase inhibitor Substances 0.000 claims description 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 2
- 229960000215 ruxolitinib Drugs 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 239000002732 sphingomyelin phosphodiesterase inhibitor Substances 0.000 claims description 2
- 229950006315 spirogermanium Drugs 0.000 claims description 2
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims description 2
- 231100000617 superantigen Toxicity 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 claims description 2
- 229960001350 tofacitinib Drugs 0.000 claims description 2
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 2
- SYIKUFDOYJFGBQ-YLAFAASESA-N tofacitinib citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 SYIKUFDOYJFGBQ-YLAFAASESA-N 0.000 claims description 2
- 229960004247 tofacitinib citrate Drugs 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 102000001712 STAT5 Transcription Factor Human genes 0.000 claims 4
- 101710163923 Jouberin Proteins 0.000 claims 3
- 230000003796 beauty Effects 0.000 claims 3
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 claims 2
- 102000004338 Transferrin Human genes 0.000 claims 2
- 108090000901 Transferrin Proteins 0.000 claims 2
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 claims 2
- 239000012581 transferrin Substances 0.000 claims 2
- 239000010938 white gold Substances 0.000 claims 2
- 229910000832 white gold Inorganic materials 0.000 claims 2
- QNOCRUSVMMAKSC-CCEZHUSRSA-N (3e)-1-methyl-3-(2-oxo-1h-indol-3-ylidene)indol-2-one Chemical compound C12=CC=CC=C2N(C)C(=O)\C1=C\1C2=CC=CC=C2NC/1=O QNOCRUSVMMAKSC-CCEZHUSRSA-N 0.000 claims 1
- ZYFONFJPXBIBLI-KBMWBBLPSA-N (4r)-4-[(8r,9s,10s,13r,14s,17r)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanamide Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(N)=O)C)[C@@]1(C)CC2 ZYFONFJPXBIBLI-KBMWBBLPSA-N 0.000 claims 1
- DOUMFZQKYFQNTF-GIZXNFQBSA-N (S)-rosmarinic acid Chemical compound C([C@@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-GIZXNFQBSA-N 0.000 claims 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims 1
- ZZVDXRCAGGQFAK-UHFFFAOYSA-N 2h-oxazaphosphinine Chemical class N1OC=CC=P1 ZZVDXRCAGGQFAK-UHFFFAOYSA-N 0.000 claims 1
- MHJBZVSGOZTKRH-IZHYLOQSSA-N 4-Hydroxy-N-desmethyltamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)/C1=CC=C(O)C=C1 MHJBZVSGOZTKRH-IZHYLOQSSA-N 0.000 claims 1
- 229940122098 Angiopoietin-like 4 protein inhibitor Drugs 0.000 claims 1
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 1
- 101000796998 Bacillus subtilis (strain 168) Methylated-DNA-protein-cysteine methyltransferase, inducible Proteins 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- 102000052052 Casein Kinase II Human genes 0.000 claims 1
- 108010010919 Casein Kinase II Proteins 0.000 claims 1
- 229940121737 Choline kinase inhibitor Drugs 0.000 claims 1
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 claims 1
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 claims 1
- 229940094664 Cysteine protease inhibitor Drugs 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 claims 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 1
- 235000021360 Myristic acid Nutrition 0.000 claims 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 1
- 229940123690 Raf kinase inhibitor Drugs 0.000 claims 1
- 229940122171 Sphingomyelinase inhibitor Drugs 0.000 claims 1
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims 1
- 229940122954 Transcription factor inhibitor Drugs 0.000 claims 1
- CGDVTHXZWRUGDF-UHFFFAOYSA-N [5-[6-(morpholin-4-ylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]urea Chemical compound NC(=O)Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1 CGDVTHXZWRUGDF-UHFFFAOYSA-N 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 229950008814 momelotinib Drugs 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 102000051624 phosphatidylethanolamine binding protein Human genes 0.000 claims 1
- 108700021017 phosphatidylethanolamine binding protein Proteins 0.000 claims 1
- 108091006084 receptor activators Proteins 0.000 claims 1
- 229950009919 saracatinib Drugs 0.000 claims 1
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 79
- 125000000217 alkyl group Chemical group 0.000 description 69
- 125000003118 aryl group Chemical group 0.000 description 41
- 125000001424 substituent group Chemical group 0.000 description 40
- 102000054765 polymorphisms of proteins Human genes 0.000 description 32
- 230000004044 response Effects 0.000 description 32
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 31
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 31
- 208000032839 leukemia Diseases 0.000 description 30
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 29
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 26
- 210000000130 stem cell Anatomy 0.000 description 25
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 22
- 125000005842 heteroatom Chemical group 0.000 description 21
- 229960003685 imatinib mesylate Drugs 0.000 description 21
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 21
- 239000000651 prodrug Substances 0.000 description 21
- 229940002612 prodrug Drugs 0.000 description 21
- 102100039064 Interleukin-3 Human genes 0.000 description 20
- 108010002386 Interleukin-3 Proteins 0.000 description 20
- 229950010913 mitolactol Drugs 0.000 description 19
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 17
- 102000000395 SH3 domains Human genes 0.000 description 17
- 108050008861 SH3 domains Proteins 0.000 description 17
- 125000003342 alkenyl group Chemical group 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 230000026731 phosphorylation Effects 0.000 description 17
- 238000006366 phosphorylation reaction Methods 0.000 description 17
- 125000005843 halogen group Chemical group 0.000 description 16
- 229910052717 sulfur Inorganic materials 0.000 description 16
- 238000001994 activation Methods 0.000 description 15
- 125000000304 alkynyl group Chemical group 0.000 description 15
- 230000002018 overexpression Effects 0.000 description 15
- 150000003431 steroids Chemical class 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 15
- 125000001072 heteroaryl group Chemical group 0.000 description 14
- 125000000623 heterocyclic group Chemical group 0.000 description 14
- 229910052757 nitrogen Inorganic materials 0.000 description 14
- 229910052760 oxygen Inorganic materials 0.000 description 14
- 125000002252 acyl group Chemical group 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 13
- 238000002512 chemotherapy Methods 0.000 description 13
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 102100035548 Protein Bop Human genes 0.000 description 12
- 108050008794 Protein Bop Proteins 0.000 description 12
- 125000003710 aryl alkyl group Chemical group 0.000 description 12
- 230000008901 benefit Effects 0.000 description 12
- 125000005647 linker group Chemical group 0.000 description 12
- 230000007246 mechanism Effects 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 230000001629 suppression Effects 0.000 description 12
- 125000000753 cycloalkyl group Chemical group 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 125000004404 heteroalkyl group Chemical group 0.000 description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 208000020816 lung neoplasm Diseases 0.000 description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 11
- 108010087686 src-Family Kinases Proteins 0.000 description 11
- 102000009076 src-Family Kinases Human genes 0.000 description 11
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 10
- 102000051485 Bcl-2 family Human genes 0.000 description 10
- 108700038897 Bcl-2 family Proteins 0.000 description 10
- 102100032305 Bcl-2 homologous antagonist/killer Human genes 0.000 description 10
- 101000798320 Homo sapiens Bcl-2 homologous antagonist/killer Proteins 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 238000007726 management method Methods 0.000 description 10
- 230000001686 pro-survival effect Effects 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 108700024394 Exon Proteins 0.000 description 9
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 9
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 230000000861 pro-apoptotic effect Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 8
- 108700020796 Oncogene Proteins 0.000 description 8
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 229940121647 egfr inhibitor Drugs 0.000 description 8
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 8
- 229960002584 gefitinib Drugs 0.000 description 8
- 230000009368 gene silencing by RNA Effects 0.000 description 8
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 201000005202 lung cancer Diseases 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 7
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000000711 cancerogenic effect Effects 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 231100000315 carcinogenic Toxicity 0.000 description 7
- 230000001332 colony forming effect Effects 0.000 description 7
- 230000002074 deregulated effect Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000003442 weekly effect Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
- 101100218425 Gallus gallus BCL2L1 gene Proteins 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 108020004459 Small interfering RNA Proteins 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 230000003474 anti-emetic effect Effects 0.000 description 6
- 239000002111 antiemetic agent Substances 0.000 description 6
- 108700000711 bcl-X Proteins 0.000 description 6
- 102000055104 bcl-X Human genes 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000003803 thymidine kinase inhibitor Substances 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 5
- 102000003964 Histone deacetylase Human genes 0.000 description 5
- 108090000353 Histone deacetylase Proteins 0.000 description 5
- 102000008072 Lymphokines Human genes 0.000 description 5
- 108010074338 Lymphokines Proteins 0.000 description 5
- 102000043276 Oncogene Human genes 0.000 description 5
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 5
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 5
- 102000015690 Proto-Oncogene Proteins c-bcr Human genes 0.000 description 5
- 108010024221 Proto-Oncogene Proteins c-bcr Proteins 0.000 description 5
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 5
- 229940123056 Thymidine kinase inhibitor Drugs 0.000 description 5
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 125000002837 carbocyclic group Chemical group 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 229960001338 colchicine Drugs 0.000 description 5
- 230000003831 deregulation Effects 0.000 description 5
- 229960003722 doxycycline Drugs 0.000 description 5
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 description 5
- 239000000367 immunologic factor Substances 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 231100000590 oncogenic Toxicity 0.000 description 5
- 230000002246 oncogenic effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000004055 small Interfering RNA Substances 0.000 description 5
- 230000002459 sustained effect Effects 0.000 description 5
- ZASCXWTVGGZQIZ-UHFFFAOYSA-N thieno[3,2-d]pyrimidin-2-amine Chemical compound NC1=NC=C2SC=CC2=N1 ZASCXWTVGGZQIZ-UHFFFAOYSA-N 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 206010069754 Acquired gene mutation Diseases 0.000 description 4
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 4
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 102000052575 Proto-Oncogene Human genes 0.000 description 4
- 108700020978 Proto-Oncogene Proteins 0.000 description 4
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 4
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 4
- 206010042971 T-cell lymphoma Diseases 0.000 description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000002424 anti-apoptotic effect Effects 0.000 description 4
- 229940124599 anti-inflammatory drug Drugs 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 4
- 229940120638 avastin Drugs 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 230000011132 hemopoiesis Effects 0.000 description 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 150000002924 oxiranes Chemical group 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 230000006916 protein interaction Effects 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 230000037439 somatic mutation Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 229960004964 temozolomide Drugs 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102100035656 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Human genes 0.000 description 3
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 description 3
- 208000004860 Blast Crisis Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102100021906 Cyclin-O Human genes 0.000 description 3
- 102400001368 Epidermal growth factor Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000803294 Homo sapiens BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Proteins 0.000 description 3
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 3
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 3
- 108700006140 Myeloid Cell Leukemia Sequence 1 Proteins 0.000 description 3
- 102000046234 Myeloid Cell Leukemia Sequence 1 Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102000001332 SRC Human genes 0.000 description 3
- 108060006706 SRC Proteins 0.000 description 3
- 102100023132 Transcription factor Jun Human genes 0.000 description 3
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 3
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 229940125683 antiemetic agent Drugs 0.000 description 3
- 230000005735 apoptotic response Effects 0.000 description 3
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 3
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 3
- 229960002707 bendamustine Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001815 biotherapy Methods 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000004452 carbocyclyl group Chemical group 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 3
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 229940082789 erbitux Drugs 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 3
- 235000008191 folinic acid Nutrition 0.000 description 3
- 239000011672 folinic acid Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 229940022353 herceptin Drugs 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229960001691 leucovorin Drugs 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 208000004235 neutropenia Diseases 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 108091008819 oncoproteins Proteins 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 3
- 210000004214 philadelphia chromosome Anatomy 0.000 description 3
- 230000010399 physical interaction Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 150000003057 platinum Chemical class 0.000 description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 208000037922 refractory disease Diseases 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010043554 thrombocytopenia Diseases 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 229940066958 treanda Drugs 0.000 description 3
- 125000004953 trihalomethyl group Chemical group 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- KNIFXFQDTOLZIJ-UHFFFAOYSA-N (2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamic acid Chemical compound N=1C2=CC(NC(=O)O)=CN=C2NC=1C1=CC=CC=C1 KNIFXFQDTOLZIJ-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 2
- RCWISWVYKNLXHC-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound NC1=CC=NC2=C1C=CN2 RCWISWVYKNLXHC-UHFFFAOYSA-N 0.000 description 2
- RZCJYMOBWVJQGV-UHFFFAOYSA-N 2-naphthyloxyacetic acid Chemical compound C1=CC=CC2=CC(OCC(=O)O)=CC=C21 RZCJYMOBWVJQGV-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 108010087905 Adenovirus E1B Proteins Proteins 0.000 description 2
- 208000004736 B-Cell Leukemia Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 108091012583 BCL2 Proteins 0.000 description 2
- 102000004276 BCL2-related protein A1 Human genes 0.000 description 2
- 108090000879 BCL2-related protein A1 Proteins 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 2
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 2
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 2
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 2
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 2
- 101150021395 JUND gene Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 2
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 102100025803 Progesterone receptor Human genes 0.000 description 2
- 102000014400 SH2 domains Human genes 0.000 description 2
- 108050003452 SH2 domains Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 108010017842 Telomerase Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108010092464 Urate Oxidase Proteins 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000000567 anti-anemic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000005756 apoptotic signaling Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 108700039689 bcl-2 Homologous Antagonist-Killer Proteins 0.000 description 2
- 102000055574 bcl-2 Homologous Antagonist-Killer Human genes 0.000 description 2
- 108700000707 bcl-2-Associated X Proteins 0.000 description 2
- 102000055102 bcl-2-Associated X Human genes 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000002079 cooperative effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000002559 cytogenic effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 102000013035 dynein heavy chain Human genes 0.000 description 2
- 108060002430 dynein heavy chain Proteins 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000000267 erythroid cell Anatomy 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 229940080856 gleevec Drugs 0.000 description 2
- 150000004548 gossypol derivatives Chemical class 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002743 insertional mutagenesis Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229960003350 isoniazid Drugs 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 150000002546 isoxazolidines Chemical class 0.000 description 2
- 239000000832 lactitol Substances 0.000 description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 2
- 235000010448 lactitol Nutrition 0.000 description 2
- 229960003451 lactitol Drugs 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 2
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 2
- 231100001143 noxa Toxicity 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 2
- 150000003217 pyrazoles Chemical class 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 102000034285 signal transducing proteins Human genes 0.000 description 2
- 108091006024 signal transducing proteins Proteins 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000009494 specialized coating Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000009452 underexpressoin Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- CVCLJVVBHYOXDC-IAZSKANUSA-N (2z)-2-[(5z)-5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole Chemical group COC1=C\C(=C/2N=C3C=CC=CC3=C\2)N\C1=C/C=1NC(C)=CC=1C CVCLJVVBHYOXDC-IAZSKANUSA-N 0.000 description 1
- FHSRUXRMSRJDQV-ZSOIEALJSA-N (3z)-2-oxo-3-(4,5,6,7-tetrahydro-1h-indol-2-ylmethylidene)-1h-indole-5-sulfonamide Chemical compound C1CCCC(N2)=C1C=C2\C=C1/C(=O)NC2=CC=C(S(=O)(=O)N)C=C21 FHSRUXRMSRJDQV-ZSOIEALJSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- ZRQPLIOJDVHTNM-UHFFFAOYSA-N 1-ethyl-3-[2-methoxy-4-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]urea Chemical compound C1=C(OC)C(NC(=O)NCC)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 ZRQPLIOJDVHTNM-UHFFFAOYSA-N 0.000 description 1
- TXPGVEQROBPCHN-UHFFFAOYSA-N 1-ethyl-3-[4-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]-2-(trifluoromethoxy)phenyl]urea Chemical compound C1=C(OC(F)(F)F)C(NC(=O)NCC)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 TXPGVEQROBPCHN-UHFFFAOYSA-N 0.000 description 1
- PHTBBLCJUSOPTQ-UHFFFAOYSA-N 1-phenylethyl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound C=1C=CC=CC=1C(C)OC(=O)NC(C=C1N=2)=CN=C1NC=2C1=CC=CC=C1 PHTBBLCJUSOPTQ-UHFFFAOYSA-N 0.000 description 1
- PMZDQRJGMBOQBF-UHFFFAOYSA-N 1H-quinolin-4-one Natural products C1=CC=C2C(O)=CC=NC2=C1 PMZDQRJGMBOQBF-UHFFFAOYSA-N 0.000 description 1
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical group C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- BYHPYNMDJCZORZ-UHFFFAOYSA-N 2,2-dimethylpropyl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OCC(C)(C)C)=CN=C2NC=1C1=CC=CC=C1 BYHPYNMDJCZORZ-UHFFFAOYSA-N 0.000 description 1
- HPXNDPIHESDYPK-UHFFFAOYSA-N 2,2-dimethylpropyl n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)carbamate Chemical compound C=1C2=CC(NC(=O)OCC(C)(C)C)=CN=C2NC=1C1=CC=CC=C1 HPXNDPIHESDYPK-UHFFFAOYSA-N 0.000 description 1
- ZIYBBNHVNXNGME-UHFFFAOYSA-N 2,2-dimethylpropyl n-[2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NC(=O)OCC(C)(C)C)C=C3C=2)=C1 ZIYBBNHVNXNGME-UHFFFAOYSA-N 0.000 description 1
- ZQMVDTJFDXBTJI-UHFFFAOYSA-N 2,4-dichloro-n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)benzamide Chemical compound ClC1=CC(Cl)=CC=C1C(=O)NC1=CN=C(NC(=C2)C=3C=CC=CC=3)C2=C1 ZQMVDTJFDXBTJI-UHFFFAOYSA-N 0.000 description 1
- AYKMXKNVEUMLFQ-UHFFFAOYSA-N 2-(1,8-naphthyridin-2-yl)phenol Chemical compound OC1=CC=CC=C1C1=CC=C(C=CC=N2)C2=N1 AYKMXKNVEUMLFQ-UHFFFAOYSA-N 0.000 description 1
- QFNJFVBKASKGEU-UHFFFAOYSA-N 2-(diethylaminomethyl)-4-[4-[3-(diethylaminomethyl)-4-hydroxyphenyl]hex-3-en-3-yl]phenol Chemical compound C1=C(O)C(CN(CC)CC)=CC(C(CC)=C(CC)C=2C=C(CN(CC)CC)C(O)=CC=2)=C1 QFNJFVBKASKGEU-UHFFFAOYSA-N 0.000 description 1
- QOWRMFBXXDITMF-UHFFFAOYSA-N 2-[(2-chloro-6-fluorophenyl)methylsulfanyl]-3-pyridin-3-ylquinazolin-4-one Chemical compound FC1=CC=CC(Cl)=C1CSC1=NC2=CC=CC=C2C(=O)N1C1=CC=CN=C1 QOWRMFBXXDITMF-UHFFFAOYSA-N 0.000 description 1
- KNBUNOSCNAVNTI-UHFFFAOYSA-N 2-[(4-methoxycarbonylphenyl)methylsulfanyl]-5-methyl-4-oxo-3h-thieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound C1=CC(C(=O)OC)=CC=C1CSC(NC1=O)=NC2=C1C(C)=C(C(O)=O)S2 KNBUNOSCNAVNTI-UHFFFAOYSA-N 0.000 description 1
- GGTQWMLKKHJMBE-UHFFFAOYSA-N 2-[4-[[4-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]amino]phenyl]acetonitrile Chemical compound C1=CC(CC#N)=CC=C1NC1=NC(NC=2NN=C(C=2)C2CC2)=CC(C=2C=CC=CC=2)=N1 GGTQWMLKKHJMBE-UHFFFAOYSA-N 0.000 description 1
- WWMBEHFXPLFIKW-UHFFFAOYSA-N 2-[6-(4-bromophenyl)-3-cyano-4-(trifluoromethyl)pyridin-2-yl]sulfanyl-2-phenylacetic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)SC(C(=C(C=1)C(F)(F)F)C#N)=NC=1C1=CC=C(Br)C=C1 WWMBEHFXPLFIKW-UHFFFAOYSA-N 0.000 description 1
- JKNWAFAZWXJCNI-UHFFFAOYSA-N 2-chloro-5-methoxy-n-[2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]benzamide Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC=C(OC)C=4)Cl)C=C3C=2)=C1 JKNWAFAZWXJCNI-UHFFFAOYSA-N 0.000 description 1
- QJKJYVUMPWSRNR-UHFFFAOYSA-N 2-chloro-6-methyl-n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)benzamide Chemical compound CC1=CC=CC(Cl)=C1C(=O)NC1=CN=C(NC(=C2)C=3C=CC=CC=3)C2=C1 QJKJYVUMPWSRNR-UHFFFAOYSA-N 0.000 description 1
- UREYTGOXKPZHBE-UHFFFAOYSA-N 2-chloro-n-[2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]benzamide Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC=CC=4)Cl)C=C3C=2)=C1 UREYTGOXKPZHBE-UHFFFAOYSA-N 0.000 description 1
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- XTCFBKIVOOQFOL-UHFFFAOYSA-N 2-methoxy-n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)benzamide Chemical compound COC1=CC=CC=C1C(=O)NC1=CN=C(NC(=C2)C=3C=CC=CC=3)C2=C1 XTCFBKIVOOQFOL-UHFFFAOYSA-N 0.000 description 1
- SETYDCSRABYHSW-UHFFFAOYSA-N 2-methyl-1-phenyl-4-pyridin-2-yl-2-(2-pyridin-2-ylethyl)butan-1-one Chemical compound C=1C=CC=NC=1CCC(C(=O)C=1C=CC=CC=1)(C)CCC1=CC=CC=N1 SETYDCSRABYHSW-UHFFFAOYSA-N 0.000 description 1
- AYMLVCPBMMFLEN-UHFFFAOYSA-N 2-methyl-N-(4-morpholin-4-ylphenyl)-2H-pyrrol-5-amine Chemical compound CC1C=CC(=N1)NC1=CC=C(C=C1)N1CCOCC1 AYMLVCPBMMFLEN-UHFFFAOYSA-N 0.000 description 1
- TURQCRWQWVIZHT-UHFFFAOYSA-N 2-methyl-n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)benzamide Chemical compound CC1=CC=CC=C1C(=O)NC1=CN=C(NC(=C2)C=3C=CC=CC=3)C2=C1 TURQCRWQWVIZHT-UHFFFAOYSA-N 0.000 description 1
- GAVKNRNMAYRKGF-UHFFFAOYSA-N 2-methylpropyl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OCC(C)C)=CN=C2NC=1C1=CC=CC=C1 GAVKNRNMAYRKGF-UHFFFAOYSA-N 0.000 description 1
- MIMJXSJUUSBBRB-UHFFFAOYSA-N 2-methylpropyl n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)carbamate Chemical compound C=1C2=CC(NC(=O)OCC(C)C)=CN=C2NC=1C1=CC=CC=C1 MIMJXSJUUSBBRB-UHFFFAOYSA-N 0.000 description 1
- RYBBEFMHXRQDHN-UHFFFAOYSA-N 2-methylpropyl n-[2-(3-acetamidophenyl)-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound C=1C2=CC(NC(=O)OCC(C)C)=CN=C2NC=1C1=CC=CC(NC(C)=O)=C1 RYBBEFMHXRQDHN-UHFFFAOYSA-N 0.000 description 1
- UKCDFOJVIJJIFR-UHFFFAOYSA-N 2-methylpropyl n-[2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NC(=O)OCC(C)C)C=C3C=2)=C1 UKCDFOJVIJJIFR-UHFFFAOYSA-N 0.000 description 1
- SQVGGCUCEJWTDH-UHFFFAOYSA-N 2-methylpropyl n-[2-[4-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound C1=CC(OCCOC)=CC=C1C1=CC2=CC(NC(=O)OCC(C)C)=CN=C2N1 SQVGGCUCEJWTDH-UHFFFAOYSA-N 0.000 description 1
- IBOIYDXLUJSBBN-UHFFFAOYSA-N 2-n-(1h-benzimidazol-2-yl)-6-(methoxymethyl)-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N=1C(NC=2NC3=CC=CC=C3N=2)=NC(COC)=CC=1NC1=CC(C)=NN1 IBOIYDXLUJSBBN-UHFFFAOYSA-N 0.000 description 1
- QFJPVWJKWACZJQ-UHFFFAOYSA-N 2-n-(3-chlorophenyl)-4-n-(5-methyl-1h-pyrazol-3-yl)-6-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C(NC=3C=C(Cl)C=CC=3)N=C(NC=3NN=C(C)C=3)C=2)=C1 QFJPVWJKWACZJQ-UHFFFAOYSA-N 0.000 description 1
- IJSRTFJVVRBSIZ-UHFFFAOYSA-N 2-n-(3-chlorophenyl)-6-(3-nitrophenyl)-4-n-(5-phenyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound [O-][N+](=O)C1=CC=CC(C=2N=C(NC=3C=C(Cl)C=CC=3)N=C(NC=3NN=C(C=3)C=3C=CC=CC=3)C=2)=C1 IJSRTFJVVRBSIZ-UHFFFAOYSA-N 0.000 description 1
- MCKQFIYONNWMAQ-UHFFFAOYSA-N 2-n-(4-chlorophenyl)-5,6-dimethyl-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=CC(Cl)=CC=2)=NC(C)=C1C MCKQFIYONNWMAQ-UHFFFAOYSA-N 0.000 description 1
- QPDOXHISZYSROD-UHFFFAOYSA-N 2-n-(4-chlorophenyl)-6-(methoxymethyl)-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N=1C(NC=2C=CC(Cl)=CC=2)=NC(COC)=CC=1NC1=CC(C)=NN1 QPDOXHISZYSROD-UHFFFAOYSA-N 0.000 description 1
- UQHSUJAJNCDBDL-UHFFFAOYSA-N 2-n-(4-chlorophenyl)-6-ethyl-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N=1C(NC=2C=CC(Cl)=CC=2)=NC(CC)=CC=1NC1=CC(C)=NN1 UQHSUJAJNCDBDL-UHFFFAOYSA-N 0.000 description 1
- WKINCHQAJSVMRX-UHFFFAOYSA-N 2-n-(4-morpholin-4-ylphenyl)-7-n-(2-propan-2-ylphenyl)thieno[3,2-d]pyrimidine-2,7-diamine Chemical compound CC(C)C1=CC=CC=C1NC(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 WKINCHQAJSVMRX-UHFFFAOYSA-N 0.000 description 1
- ZQVDLGSARPZTIJ-UHFFFAOYSA-N 2-phenyl-n-(1-phenylethyl)-1h-imidazo[4,5-b]pyridin-6-amine Chemical compound C=1C=CC=CC=1C(C)NC(C=C1N=2)=CN=C1NC=2C1=CC=CC=C1 ZQVDLGSARPZTIJ-UHFFFAOYSA-N 0.000 description 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- RGNQQYKNWHKCES-UHFFFAOYSA-N 3-(2-hydroxyphenyl)-3-phenyl-n,n-dipropylpropanamide Chemical compound C=1C=CC=C(O)C=1C(CC(=O)N(CCC)CCC)C1=CC=CC=C1 RGNQQYKNWHKCES-UHFFFAOYSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- VYQUIYSWCNUIBL-UHFFFAOYSA-N 3-[6-(propan-2-yloxycarbonylamino)-1h-imidazo[4,5-b]pyridin-2-yl]benzoic acid Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=CC(C(O)=O)=C1 VYQUIYSWCNUIBL-UHFFFAOYSA-N 0.000 description 1
- FSGGEXBJTHFCHP-UHFFFAOYSA-N 3-amino-2-(2-chloro-5-hydroxyphenyl)-7-(2-morpholin-4-ylethoxy)-5H-pyrazolo[4,3-c]quinolin-4-one Chemical compound NC=1N(C=2C(=CC=C(O)C=2)Cl)N=C(C2=CC=3)C=1C(=O)NC2=CC=3OCCN1CCOCC1 FSGGEXBJTHFCHP-UHFFFAOYSA-N 0.000 description 1
- AKEYKEPZDYXZOH-UHFFFAOYSA-N 3-amino-2-(2-chloro-5-hydroxyphenyl)-7-(3-morpholin-4-ylpropoxy)-5H-pyrazolo[4,3-c]quinolin-4-one Chemical compound NC=1N(C=2C(=CC=C(O)C=2)Cl)N=C(C2=CC=3)C=1C(=O)NC2=CC=3OCCCN1CCOCC1 AKEYKEPZDYXZOH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- BTKZNPLSNZGUGX-UHFFFAOYSA-N 3-methylbutan-2-yl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C(C)C)=CN=C2NC=1C1=CC=CC=C1 BTKZNPLSNZGUGX-UHFFFAOYSA-N 0.000 description 1
- MEYPDIZQUOKSNV-UHFFFAOYSA-N 3-n-(7-iodothieno[3,2-d]pyrimidin-2-yl)benzene-1,3-diamine Chemical compound NC1=CC=CC(NC=2N=C3C(I)=CSC3=CN=2)=C1 MEYPDIZQUOKSNV-UHFFFAOYSA-N 0.000 description 1
- YFQIRHIHDGHORF-UHFFFAOYSA-N 3-n-[7-(2-ethylphenyl)thieno[3,2-d]pyrimidin-2-yl]benzene-1,3-diamine Chemical compound CCC1=CC=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=CC(N)=C1 YFQIRHIHDGHORF-UHFFFAOYSA-N 0.000 description 1
- TXTQURPQLVHJRE-UHFFFAOYSA-N 3-nitrobenzenesulfonamide Chemical group NS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 TXTQURPQLVHJRE-UHFFFAOYSA-N 0.000 description 1
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 1
- KQBVVLOYXDVATK-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-indole Chemical compound C1CCCC2=C1C=CN2 KQBVVLOYXDVATK-UHFFFAOYSA-N 0.000 description 1
- KRCUAJDZUQDXRN-FQEVSTJZSA-N 4-[(1s)-6,7-diethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]benzonitrile Chemical compound C1([C@@H]2NCCC=3C=C(C(=CC=32)OCC)OCC)=CC=C(C#N)C=C1 KRCUAJDZUQDXRN-FQEVSTJZSA-N 0.000 description 1
- BWLNKXHOUJNNEL-UHFFFAOYSA-N 4-[4-(morpholin-4-ylmethyl)phenyl]thieno[3,2-d]pyrimidin-2-amine Chemical compound O1CCN(CC1)CC1=CC=C(C=C1)C=1C2=C(N=C(N=1)N)C=CS2 BWLNKXHOUJNNEL-UHFFFAOYSA-N 0.000 description 1
- BAELVIMBCBALND-UHFFFAOYSA-N 4-[[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-(3,4,5-trimethoxyphenyl)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C(NC=3C=CC(=CC=3)S(N)(=O)=O)N=C(NC=3NN=C(C)C=3)C=2)=C1 BAELVIMBCBALND-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- IYLIRRZCLARWKQ-UHFFFAOYSA-N 4-anilinoquinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=CC=CC2=C1NC1=CC=CC=C1 IYLIRRZCLARWKQ-UHFFFAOYSA-N 0.000 description 1
- WMKROGNCHRZZSN-UHFFFAOYSA-N 4-bromo-N-(3,4-dimethoxyphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound BrC=1C2=C(N=C(N=1)NC1=CC(=C(C=C1)OC)OC)C=CS2 WMKROGNCHRZZSN-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
- LRACMIDLSWCJHK-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n,6-diphenylpyrimidine-2,4-diamine Chemical compound C1CC1C1=NNC(NC=2N=C(NC=3C=CC=CC=3)N=C(C=2)C=2C=CC=CC=2)=C1 LRACMIDLSWCJHK-UHFFFAOYSA-N 0.000 description 1
- NUPWYKBBNYGZGV-UHFFFAOYSA-N 4-n-(5-tert-butyl-1h-pyrazol-3-yl)-2-n-(3-chlorophenyl)-6-(3-nitrophenyl)pyrimidine-2,4-diamine Chemical compound N1N=C(C(C)(C)C)C=C1NC1=CC(C=2C=C(C=CC=2)[N+]([O-])=O)=NC(NC=2C=C(Cl)C=CC=2)=N1 NUPWYKBBNYGZGV-UHFFFAOYSA-N 0.000 description 1
- DDLGKYQTGUWEJS-UHFFFAOYSA-N 4-n-[5-(furan-2-yl)-1h-pyrazol-3-yl]-2-n,6-diphenylpyrimidine-2,4-diamine Chemical compound C=1C(C=2C=CC=CC=2)=NC(NC=2C=CC=CC=2)=NC=1NC(NN=1)=CC=1C1=CC=CO1 DDLGKYQTGUWEJS-UHFFFAOYSA-N 0.000 description 1
- TXCMFODSFLTCNK-UHFFFAOYSA-N 5,6-dimethyl-4-n-(5-methyl-1h-pyrazol-3-yl)-2-n-phenylpyrimidine-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=CC=CC=2)=NC(C)=C1C TXCMFODSFLTCNK-UHFFFAOYSA-N 0.000 description 1
- SAPCUZGFJUFXGF-UHFFFAOYSA-N 5,7-diphenylpyrrolo[2,3-d]pyrimidine Chemical class C12=CN=CN=C2N(C=2C=CC=CC=2)C=C1C1=CC=CC=C1 SAPCUZGFJUFXGF-UHFFFAOYSA-N 0.000 description 1
- IVADEYIFFKRQRZ-UHFFFAOYSA-N 5-bromo-3-hydroxy-3-[2-oxo-2-(5,6,7,8-tetrahydronaphthalen-2-yl)ethyl]-1h-indol-2-one Chemical compound O=C1NC2=CC=C(Br)C=C2C1(O)CC(=O)C1=CC=C(CCCC2)C2=C1 IVADEYIFFKRQRZ-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 description 1
- FBXWZGUXNBEQGN-UHFFFAOYSA-N 6-hydroxy-7-oxobenzo[e]perimidine-4-sulfonic acid Chemical compound N1=CN=C2C3=CC=CC=C3C(=O)C3=C2C1=C(S(O)(=O)=O)C=C3O FBXWZGUXNBEQGN-UHFFFAOYSA-N 0.000 description 1
- GWZOURQFOXBJDY-UHFFFAOYSA-N 7-(2-aminopyrimidin-5-yl)-n-(3,4-dimethoxyphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(SC=C2C=3C=NC(N)=NC=3)C2=N1 GWZOURQFOXBJDY-UHFFFAOYSA-N 0.000 description 1
- FVLDKKBZEPCRSZ-UHFFFAOYSA-N 7-(2-aminopyrimidin-5-yl)-n-[4-(morpholin-4-ylmethyl)phenyl]thieno[3,2-d]pyrimidin-2-amine Chemical compound C1=NC(N)=NC=C1C(C1=N2)=CSC1=CN=C2NC(C=C1)=CC=C1CN1CCOCC1 FVLDKKBZEPCRSZ-UHFFFAOYSA-N 0.000 description 1
- RMDPEJUOCPZKEC-UHFFFAOYSA-N 7-(2-ethylphenyl)-n-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound CCC1=CC=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 RMDPEJUOCPZKEC-UHFFFAOYSA-N 0.000 description 1
- NFZPTELINVMKMR-UHFFFAOYSA-N 7-(2-methoxypyridin-3-yl)-n-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound COC1=NC=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 NFZPTELINVMKMR-UHFFFAOYSA-N 0.000 description 1
- ZVQHOLKTOFURIS-UHFFFAOYSA-N 7-(3-aminophenyl)-n-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound NC1=CC=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 ZVQHOLKTOFURIS-UHFFFAOYSA-N 0.000 description 1
- GPVTXRKZDLMLOL-UHFFFAOYSA-N 7-(4-amino-3-methoxyphenyl)-n-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound C1=C(N)C(OC)=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 GPVTXRKZDLMLOL-UHFFFAOYSA-N 0.000 description 1
- LSVRDFWXFIOTPD-UHFFFAOYSA-N 7-(4-amino-3-nitrophenyl)-n-(3,4-dimethoxyphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(SC=C2C=3C=C(C(N)=CC=3)[N+]([O-])=O)C2=N1 LSVRDFWXFIOTPD-UHFFFAOYSA-N 0.000 description 1
- BNZDPWAUHORUCL-UHFFFAOYSA-N 7-(4-amino-3-nitrophenyl)-n-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound C1=C([N+]([O-])=O)C(N)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 BNZDPWAUHORUCL-UHFFFAOYSA-N 0.000 description 1
- PAUFNAVZOJBUAW-UHFFFAOYSA-N 7-(4-aminophenyl)-n-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound C1=CC(N)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 PAUFNAVZOJBUAW-UHFFFAOYSA-N 0.000 description 1
- HQYFNRUBVMRJHK-UHFFFAOYSA-N 7-[4-(4-methylpiperazin-1-yl)phenyl]-n-[4-(morpholin-4-ylmethyl)phenyl]thieno[3,2-d]pyrimidin-2-amine Chemical compound C1CN(C)CCN1C1=CC=C(C=2C3=NC(NC=4C=CC(CN5CCOCC5)=CC=4)=NC=C3SC=2)C=C1 HQYFNRUBVMRJHK-UHFFFAOYSA-N 0.000 description 1
- ZIUVZAUZRMYGTO-UHFFFAOYSA-N 7-[4-(aminomethyl)phenyl]-n-[4-(morpholin-4-ylmethyl)phenyl]thieno[3,2-d]pyrimidin-2-amine Chemical compound C1=CC(CN)=CC=C1C(C1=N2)=CSC1=CN=C2NC(C=C1)=CC=C1CN1CCOCC1 ZIUVZAUZRMYGTO-UHFFFAOYSA-N 0.000 description 1
- ZRSLVQISLPSOLF-UHFFFAOYSA-N 7-[4-amino-3-(trifluoromethoxy)phenyl]-n-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound C1=C(OC(F)(F)F)C(N)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 ZRSLVQISLPSOLF-UHFFFAOYSA-N 0.000 description 1
- AVDORUKLIOLRRM-UHFFFAOYSA-N 7-bromo-n-(3,4,5-trimethoxyphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C3C(Br)=CSC3=CN=2)=C1 AVDORUKLIOLRRM-UHFFFAOYSA-N 0.000 description 1
- KTXBGBIBFVAPBD-UHFFFAOYSA-N 7-bromo-n-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound N1=C2C(Br)=CSC2=CN=C1NC(C=C1)=CC=C1N1CCOCC1 KTXBGBIBFVAPBD-UHFFFAOYSA-N 0.000 description 1
- BTIJYOTXEXMWCD-UHFFFAOYSA-N 7-bromo-n-[4-(2-pyrrolidin-1-ylethoxy)phenyl]thieno[3,2-d]pyrimidin-2-amine Chemical compound N1=C2C(Br)=CSC2=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 BTIJYOTXEXMWCD-UHFFFAOYSA-N 0.000 description 1
- FZLPMBULBHSJGD-UHFFFAOYSA-N 7-bromo-n-[4-[(4-ethylpiperazin-1-yl)methyl]phenyl]thieno[3,2-d]pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=C1)=CC=C1NC1=NC=C(SC=C2Br)C2=N1 FZLPMBULBHSJGD-UHFFFAOYSA-N 0.000 description 1
- MAWBDDBDDYIMOK-UHFFFAOYSA-N 7-ethoxyindeno[1,2-b]quinoxalin-11-one Chemical compound C1=CC=C2C3=NC4=CC(OCC)=CC=C4N=C3C(=O)C2=C1 MAWBDDBDDYIMOK-UHFFFAOYSA-N 0.000 description 1
- CRVCMLQVHOKQBS-UHFFFAOYSA-N 7-iodo-n-(3-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound N1=C2C(I)=CSC2=CN=C1NC(C=1)=CC=CC=1N1CCOCC1 CRVCMLQVHOKQBS-UHFFFAOYSA-N 0.000 description 1
- ZTRUDXLYAWTYHT-UHFFFAOYSA-N 7-iodo-n-(3-nitrophenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound [O-][N+](=O)C1=CC=CC(NC=2N=C3C(I)=CSC3=CN=2)=C1 ZTRUDXLYAWTYHT-UHFFFAOYSA-N 0.000 description 1
- JBECAGFSWOUDBK-UHFFFAOYSA-N 7-iodo-n-(4-morpholin-4-ylphenyl)-5h-pyrrolo[3,2-d]pyrimidin-2-amine Chemical compound N1=C2C(I)=CNC2=CN=C1NC(C=C1)=CC=C1N1CCOCC1 JBECAGFSWOUDBK-UHFFFAOYSA-N 0.000 description 1
- MOAKLJKOGYJRNX-UHFFFAOYSA-N 7-iodo-n-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound N1=C2C(I)=CSC2=CN=C1NC(C=C1)=CC=C1N1CCOCC1 MOAKLJKOGYJRNX-UHFFFAOYSA-N 0.000 description 1
- BIUXMWARCYGKBI-UHFFFAOYSA-N 7-iodo-n-[4-(morpholin-4-ylmethyl)phenyl]thieno[3,2-d]pyrimidin-2-amine Chemical compound N1=C2C(I)=CSC2=CN=C1NC(C=C1)=CC=C1CN1CCOCC1 BIUXMWARCYGKBI-UHFFFAOYSA-N 0.000 description 1
- HALYIFFLOBGDNN-UHFFFAOYSA-N 7h-pyrido[3,4-d]pyrimidin-8-one Chemical compound N1=CN=C2C(=O)NC=CC2=C1 HALYIFFLOBGDNN-UHFFFAOYSA-N 0.000 description 1
- PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 description 1
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100025674 Angiopoietin-related protein 4 Human genes 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 102000052666 B-Cell Lymphoma 3 Human genes 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 description 1
- 101150008012 Bcl2l1 gene Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108050001736 Bradykinin receptor Proteins 0.000 description 1
- VXAZCGLRBIQKPF-UHFFFAOYSA-N C(C)(C)C1=C(C=CC=C1)C=1C2=C(N=C(N1)NC1=CC=C(C=C1)N1CCOCC1)C=CS2 Chemical compound C(C)(C)C1=C(C=CC=C1)C=1C2=C(N=C(N1)NC1=CC=C(C=C1)N1CCOCC1)C=CS2 VXAZCGLRBIQKPF-UHFFFAOYSA-N 0.000 description 1
- VKTJOKHNMXGYGU-UHFFFAOYSA-N C(C)(C)OC(N(C=1C=C2C(=NC1)NC(=N2)C2=CC(=CC=C2)NS(=O)(=O)C)C=2C=C1C(=NC2)NC(=N1)C1=CC(=CC=C1)NC(C)=O)=O Chemical compound C(C)(C)OC(N(C=1C=C2C(=NC1)NC(=N2)C2=CC(=CC=C2)NS(=O)(=O)C)C=2C=C1C(=NC2)NC(=N1)C1=CC(=CC=C1)NC(C)=O)=O VKTJOKHNMXGYGU-UHFFFAOYSA-N 0.000 description 1
- NPMPYLRQLYWPMC-UHFFFAOYSA-N C(C)OC(NC=1C=C2C(=NC1)NC(=C2)C2=CC=CC=C2)=O.ClC2=C(COC(NC=1C=C3C(=NC1)NC(=C3)C3=CC(=CC=C3)OCCOC)=O)C=CC=C2 Chemical compound C(C)OC(NC=1C=C2C(=NC1)NC(=C2)C2=CC=CC=C2)=O.ClC2=C(COC(NC=1C=C3C(=NC1)NC(=C3)C3=CC(=CC=C3)OCCOC)=O)C=CC=C2 NPMPYLRQLYWPMC-UHFFFAOYSA-N 0.000 description 1
- OLFQOZJYWSXNNP-UHFFFAOYSA-N C(CC)OC(NC=1C=C2C(=NC1)NC(=N2)C2=CC=C(C=C2)OCCN(CC)CC)=O Chemical compound C(CC)OC(NC=1C=C2C(=NC1)NC(=N2)C2=CC=C(C=C2)OCCN(CC)CC)=O OLFQOZJYWSXNNP-UHFFFAOYSA-N 0.000 description 1
- UXYHZIYEDDINQH-UHFFFAOYSA-N C1=CNC2=C3C=NN=C3C=CC2=C1 Chemical class C1=CNC2=C3C=NN=C3C=CC2=C1 UXYHZIYEDDINQH-UHFFFAOYSA-N 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- IDLNEPOYBLHDJM-UHFFFAOYSA-N CC(C)C(C=C1)=CC=C1C1=NC(NC(C=C2)=CC=C2N2CCOCC2)=NC2=C1SC=C2N Chemical compound CC(C)C(C=C1)=CC=C1C1=NC(NC(C=C2)=CC=C2N2CCOCC2)=NC2=C1SC=C2N IDLNEPOYBLHDJM-UHFFFAOYSA-N 0.000 description 1
- IUPBEEDGDRYITQ-UHFFFAOYSA-N CC(COC(N(C=1C=C2C(=NC1)NC(=C2)C2=CC=C(C=C2)NC(C)=O)CC(C)(C)C)=O)(C)C.C(C)(=O)NC=2C=C(C=CC2)C2=CC=1C(=NC=C(C1)NC(O)=O)N2 Chemical compound CC(COC(N(C=1C=C2C(=NC1)NC(=C2)C2=CC=C(C=C2)NC(C)=O)CC(C)(C)C)=O)(C)C.C(C)(=O)NC=2C=C(C=CC2)C2=CC=1C(=NC=C(C1)NC(O)=O)N2 IUPBEEDGDRYITQ-UHFFFAOYSA-N 0.000 description 1
- JYLLTUKIPFSPND-UHFFFAOYSA-N CN1CCN(CC1)CCCOC1=CC=C2C=C(C=NC2=C1)C#N Chemical compound CN1CCN(CC1)CCCOC1=CC=C2C=C(C=NC2=C1)C#N JYLLTUKIPFSPND-UHFFFAOYSA-N 0.000 description 1
- UTGFUYYMKJUWGA-UHFFFAOYSA-N COC=1C=C(C=CC1OC)N1CN=CC2=C1C(=CS2)C2=CC=CC=C2 Chemical compound COC=1C=C(C=CC1OC)N1CN=CC2=C1C(=CS2)C2=CC=CC=C2 UTGFUYYMKJUWGA-UHFFFAOYSA-N 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 description 1
- 108010018888 Choline kinase Proteins 0.000 description 1
- 102100031065 Choline kinase alpha Human genes 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 102000010180 Endothelin receptor Human genes 0.000 description 1
- 108050001739 Endothelin receptor Proteins 0.000 description 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
- 102100028471 Eosinophil peroxidase Human genes 0.000 description 1
- 102000008175 FSH Receptors Human genes 0.000 description 1
- 108010060374 FSH Receptors Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102000011392 Galanin receptor Human genes 0.000 description 1
- 108050001605 Galanin receptor Proteins 0.000 description 1
- 102000052874 Gastrin receptors Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 1
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 description 1
- 108010063919 Glucagon Receptors Proteins 0.000 description 1
- 102100040890 Glucagon receptor Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- MCSPBPXATWBACD-GAYQJXMFSA-N Guanabenz acetate Chemical compound CC(O)=O.NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl MCSPBPXATWBACD-GAYQJXMFSA-N 0.000 description 1
- 101150054472 HER2 gene Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000693076 Homo sapiens Angiopoietin-related protein 4 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 102000023108 LH Receptors Human genes 0.000 description 1
- 108010011942 LH Receptors Proteins 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000035561 Leukaemic infiltration brain Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 101100269444 Mus musculus Ahi1 gene Proteins 0.000 description 1
- 101000971179 Mus musculus B-cell lymphoma 3 protein homolog Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 1
- 108050002826 Neuropeptide Y Receptor Proteins 0.000 description 1
- 102000012301 Neuropeptide Y receptor Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010049358 Oncogene Protein p65(gag-jun) Proteins 0.000 description 1
- 102100028139 Oxytocin receptor Human genes 0.000 description 1
- 108090000876 Oxytocin receptors Proteins 0.000 description 1
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 description 1
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 description 1
- 208000032721 Philadelphia Chromosome Diseases 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 description 1
- 108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000713810 Rat sarcoma virus Species 0.000 description 1
- 102000016983 Releasing hormones receptors Human genes 0.000 description 1
- 108070000025 Releasing hormones receptors Proteins 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 101150058731 STAT5A gene Proteins 0.000 description 1
- 101150063267 STAT5B gene Proteins 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108050001286 Somatostatin Receptor Proteins 0.000 description 1
- 102000011096 Somatostatin receptor Human genes 0.000 description 1
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 108090000253 Thyrotropin Receptors Proteins 0.000 description 1
- 102100029337 Thyrotropin receptor Human genes 0.000 description 1
- 102000005747 Transcription Factor RelA Human genes 0.000 description 1
- 108010031154 Transcription Factor RelA Proteins 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 101710098624 Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
- 101710103851 Tyrosine-protein kinase transforming protein Abl Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 101710086987 X protein Proteins 0.000 description 1
- DXWGBJJLEDQBKS-LDBVRRDLSA-N [(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-[5-hydroxy-3-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxyoxan-2-yl]methyl acetate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)C)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 DXWGBJJLEDQBKS-LDBVRRDLSA-N 0.000 description 1
- PJHSWBIUNREZQP-XVNBXDOJSA-N [(e)-pent-3-en-2-yl] n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)/C=C/C)=CN=C2NC=1C1=CC=CC=C1 PJHSWBIUNREZQP-XVNBXDOJSA-N 0.000 description 1
- DACWQSNZECJJGG-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyridine Chemical compound C1=CC=CN2N=CN=C21 DACWQSNZECJJGG-UHFFFAOYSA-N 0.000 description 1
- CNSGMDIIDUDBOM-UHFFFAOYSA-N [2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamic acid Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NC(O)=O)C=C3C=2)=C1 CNSGMDIIDUDBOM-UHFFFAOYSA-N 0.000 description 1
- LYFQKBYNAGDVHO-UHFFFAOYSA-N [3-[(7-iodothieno[3,2-d]pyrimidin-2-yl)amino]phenyl]methanol Chemical compound OCC1=CC=CC(NC=2N=C3C(I)=CSC3=CN=2)=C1 LYFQKBYNAGDVHO-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- VBAPMKXSHRDSCJ-UHFFFAOYSA-N [4-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]methanol Chemical compound C1=CC(CO)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 VBAPMKXSHRDSCJ-UHFFFAOYSA-N 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- DXWGBJJLEDQBKS-UHFFFAOYSA-N acetylgenistin Natural products OC1C(O)C(O)C(COC(=O)C)OC1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 DXWGBJJLEDQBKS-UHFFFAOYSA-N 0.000 description 1
- 229910052768 actinide Inorganic materials 0.000 description 1
- 150000001255 actinides Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000005865 alkene metathesis reaction Methods 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 description 1
- 125000005137 alkenylsulfonyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- 125000005087 alkynylcarbonyl group Chemical group 0.000 description 1
- 125000005225 alkynyloxycarbonyl group Chemical group 0.000 description 1
- 125000005139 alkynylsulfonyl group Chemical group 0.000 description 1
- RXVGBQCEAQZMLW-UHFFFAOYSA-N alpha-solanine Natural products CC1CCC2C(C)C3C(CC4C5CC=C6CC(CCC6(C)C5CCC34C)OC7OC(CO)C(O)C(OC8OC(CO)C(O)C(O)C8O)C7OC9OC(CO)C(O)C(O)C9O)N2C1 RXVGBQCEAQZMLW-UHFFFAOYSA-N 0.000 description 1
- 229960000852 alprenolol hydrochloride Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000001062 anti-nausea Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- LZSSRMGPZUCRKN-UHFFFAOYSA-N benzyl n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC(C=C1C=2)=CN=C1NC=2C1=CC=CC=C1 LZSSRMGPZUCRKN-UHFFFAOYSA-N 0.000 description 1
- UKPVXQGVJOQGPU-UHFFFAOYSA-N benzyl n-[2-(3-acetamidophenyl)-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound CC(=O)NC1=CC=CC(C=2NC3=NC=C(NC(=O)OCC=4C=CC=CC=4)C=C3C=2)=C1 UKPVXQGVJOQGPU-UHFFFAOYSA-N 0.000 description 1
- WZBONLLHYOJWHX-UHFFFAOYSA-N benzyl n-[2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NC(=O)OCC=4C=CC=CC=4)C=C3C=2)=C1 WZBONLLHYOJWHX-UHFFFAOYSA-N 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000009613 breast lymphoma Diseases 0.000 description 1
- FULYZVMODXYXHD-UHFFFAOYSA-N but-3-yn-2-yl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C#C)=CN=C2NC=1C1=CC=CC=C1 FULYZVMODXYXHD-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010039 central nervous system leukemia Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- LOLPPWBBNUVNQZ-UHFFFAOYSA-N chembl495727 Chemical compound C=1NN=C(C=2NC3=CC=C(CN4CCOCC4)C=C3N=2)C=1NC(=O)NC1CC1 LOLPPWBBNUVNQZ-UHFFFAOYSA-N 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- RPKLZQLYODPWTM-KBMWBBLPSA-N cholanoic acid Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 RPKLZQLYODPWTM-KBMWBBLPSA-N 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
- BABVUJPDRJTNND-UHFFFAOYSA-N cyclobutyl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound C1CCC1OC(=O)NC(C=C1N=2)=CN=C1NC=2C1=CC=CC=C1 BABVUJPDRJTNND-UHFFFAOYSA-N 0.000 description 1
- VFXCFKKFUPEJJE-UHFFFAOYSA-N cyclohexyl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound C1CCCCC1OC(=O)NC(C=C1N=2)=CN=C1NC=2C1=CC=CC=C1 VFXCFKKFUPEJJE-UHFFFAOYSA-N 0.000 description 1
- XFGCMPIZIRTKIG-UHFFFAOYSA-N cyclopentyl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound C1CCCC1OC(=O)NC(C=C1N=2)=CN=C1NC=2C1=CC=CC=C1 XFGCMPIZIRTKIG-UHFFFAOYSA-N 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- KWULWOZTURJEDW-UHFFFAOYSA-N dibutyl 1-cyanobutyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OC(CCC)C#N KWULWOZTURJEDW-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 229960002017 echothiophate Drugs 0.000 description 1
- BJOLKYGKSZKIGU-UHFFFAOYSA-N ecothiopate Chemical compound CCOP(=O)(OCC)SCC[N+](C)(C)C BJOLKYGKSZKIGU-UHFFFAOYSA-N 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 230000008519 endogenous mechanism Effects 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- QLVTZTHGFRDIPO-UHFFFAOYSA-N ethyl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OCC)=CN=C2NC=1C1=CC=CC=C1 QLVTZTHGFRDIPO-UHFFFAOYSA-N 0.000 description 1
- GHPQLWNDGRKPKN-UHFFFAOYSA-N ethyl n-[2-(3-acetamidophenyl)-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound C=1C2=CC(NC(=O)OCC)=CN=C2NC=1C1=CC=CC(NC(C)=O)=C1 GHPQLWNDGRKPKN-UHFFFAOYSA-N 0.000 description 1
- UUTUIHFNHYKTBH-UHFFFAOYSA-N ethyl n-[2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound C=1C2=CC(NC(=O)OCC)=CN=C2NC=1C1=CC=CC(OCCOC)=C1 UUTUIHFNHYKTBH-UHFFFAOYSA-N 0.000 description 1
- XZZWOJIKAHIYGC-UHFFFAOYSA-N ethyl n-[2-[4-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound C=1C2=CC(NC(=O)OCC)=CN=C2NC=1C1=CC=C(OCCOC)C=C1 XZZWOJIKAHIYGC-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940065734 gamma-aminobutyrate Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 210000001703 glandular epithelial cell Anatomy 0.000 description 1
- 229940084910 gliadel Drugs 0.000 description 1
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 description 1
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 description 1
- 235000008466 glycitein Nutrition 0.000 description 1
- 229930000755 gossypol Natural products 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 230000009643 growth defect Effects 0.000 description 1
- 229960003050 guanabenz acetate Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 125000003106 haloaryl group Chemical group 0.000 description 1
- 125000005216 haloheteroaryl group Chemical group 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- 239000002788 histamine agent Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000005020 hydroxyalkenyl group Chemical group 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000005016 hydroxyalkynyl group Chemical group 0.000 description 1
- 125000005027 hydroxyaryl group Chemical group 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- DCLWNTIANRACSB-UHFFFAOYSA-N imidazo[1,2-b]pyridazin-6-amine Chemical compound N1=C(N)C=CC2=NC=CN21 DCLWNTIANRACSB-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- AXESYCSCGBQJBL-SZPBEECKSA-N largazole Chemical compound O=C([C@@]1(C)N=C2SC1)N[C@@H](C(C)C)C(=O)O[C@H](/C=C/CCSC(=O)CCCCCCC)CC(=O)NCC1=NC2=CS1 AXESYCSCGBQJBL-SZPBEECKSA-N 0.000 description 1
- 108010039490 largazole Proteins 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 208000017830 lymphoblastoma Diseases 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 150000002741 methionine derivatives Chemical class 0.000 description 1
- CMUHZRATLMUDJI-UHFFFAOYSA-N methyl 2h-pyridine-1-carboxylate Chemical compound COC(=O)N1CC=CC=C1 CMUHZRATLMUDJI-UHFFFAOYSA-N 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 108700021654 myb Genes Proteins 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 230000003039 myelosuppressive effect Effects 0.000 description 1
- XDPJRGCCJOHFKO-UHFFFAOYSA-N n-(2,4-dimethoxyphenyl)-7-phenylthieno[3,2-d]pyrimidin-2-amine Chemical compound COC1=CC(OC)=CC=C1NC1=NC=C(SC=C2C=3C=CC=CC=3)C2=N1 XDPJRGCCJOHFKO-UHFFFAOYSA-N 0.000 description 1
- GVLWPGOBDOZPQA-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-7-(2,4-dimethoxypyrimidin-5-yl)thieno[3,2-d]pyrimidin-2-amine Chemical compound COC1=NC(OC)=NC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(OC)C(OC)=C1 GVLWPGOBDOZPQA-UHFFFAOYSA-N 0.000 description 1
- UDALSLVSZQGREF-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-7-(2,6-dimethoxypyridin-3-yl)thieno[3,2-d]pyrimidin-2-amine Chemical compound COC1=NC(OC)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(OC)C(OC)=C1 UDALSLVSZQGREF-UHFFFAOYSA-N 0.000 description 1
- MIRNGLYFHWGFOE-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(SC=C2C=3C(=NC=CC=3)OC)C2=N1 MIRNGLYFHWGFOE-UHFFFAOYSA-N 0.000 description 1
- PKIWVUOKEVEOIZ-UHFFFAOYSA-N n-(3-nitrophenyl)-7-phenylthieno[3,2-d]pyrimidin-2-amine Chemical compound [O-][N+](=O)C1=CC=CC(NC=2N=C3C(C=4C=CC=CC=4)=CSC3=CN=2)=C1 PKIWVUOKEVEOIZ-UHFFFAOYSA-N 0.000 description 1
- RDLKHGFOOIQELP-UHFFFAOYSA-N n-[(2-methylphenyl)methyl]-2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-amine Chemical compound CC1=CC=CC=C1CNC1=CN=C(NC(=C2)C=3C=CC=CC=3)C2=C1 RDLKHGFOOIQELP-UHFFFAOYSA-N 0.000 description 1
- QAORNCIDWJJIAL-UHFFFAOYSA-N n-[2-methoxy-4-[2-[4-(morpholin-4-ylmethyl)anilino]thieno[3,2-d]pyrimidin-7-yl]phenyl]acetamide Chemical compound C1=C(NC(C)=O)C(OC)=CC(C=2C3=NC(NC=4C=CC(CN5CCOCC5)=CC=4)=NC=C3SC=2)=C1 QAORNCIDWJJIAL-UHFFFAOYSA-N 0.000 description 1
- XQFCKSHIEBKWDU-UHFFFAOYSA-N n-[3-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 XQFCKSHIEBKWDU-UHFFFAOYSA-N 0.000 description 1
- LGTMIYZVEVWGHI-UHFFFAOYSA-N n-[3-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]prop-2-enamide Chemical compound C=CC(=O)NC1=CC=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 LGTMIYZVEVWGHI-UHFFFAOYSA-N 0.000 description 1
- RPRATBSQXQZMEI-UHFFFAOYSA-N n-[3-[2-[4-(morpholin-4-ylmethyl)anilino]thieno[3,2-d]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C=2C3=NC(NC=4C=CC(CN5CCOCC5)=CC=4)=NC=C3SC=2)=C1 RPRATBSQXQZMEI-UHFFFAOYSA-N 0.000 description 1
- RUQWOHKPZSEAPL-UHFFFAOYSA-N n-[3-[5-[(2-methylphenyl)methylamino]-1h-pyrrolo[2,3-b]pyridin-2-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2NC3=NC=C(NCC=4C(=CC=CC=4)C)C=C3C=2)=C1 RUQWOHKPZSEAPL-UHFFFAOYSA-N 0.000 description 1
- JMYOXLDNKPWWEH-UHFFFAOYSA-N n-[3-[5-methyl-2-(4-morpholin-4-ylanilino)pyrrolo[3,2-d]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound C12=NC(NC=3C=CC(=CC=3)N3CCOCC3)=NC=C2N(C)C=C1C1=CC=CC(NS(C)(=O)=O)=C1 JMYOXLDNKPWWEH-UHFFFAOYSA-N 0.000 description 1
- HTYGQYUCPPBJJY-UHFFFAOYSA-N n-[4-(morpholin-4-ylmethyl)phenyl]-7-(3-piperazin-1-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound C=1C=C(NC=2N=C3C(C=4C=C(C=CC=4)N4CCNCC4)=CSC3=CN=2)C=CC=1CN1CCOCC1 HTYGQYUCPPBJJY-UHFFFAOYSA-N 0.000 description 1
- HMEPXVKGBGJCCM-UHFFFAOYSA-N n-[4-[(4-ethylpiperazin-1-yl)methyl]phenyl]-7-(1h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=C1)=CC=C1NC1=NC=C(SC=C2C3=CNN=C3)C2=N1 HMEPXVKGBGJCCM-UHFFFAOYSA-N 0.000 description 1
- JRHMIDVQGPCTRL-UHFFFAOYSA-N n-[4-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 JRHMIDVQGPCTRL-UHFFFAOYSA-N 0.000 description 1
- OFKYPJFPTVMPEQ-UHFFFAOYSA-N n-[4-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]prop-2-enamide Chemical compound C1=CC(NC(=O)C=C)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 OFKYPJFPTVMPEQ-UHFFFAOYSA-N 0.000 description 1
- KCKBBZRCPOVAQO-UHFFFAOYSA-N n-[4-[5-(benzylamino)-1h-pyrrolo[2,3-b]pyridin-2-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=CC2=CC(NCC=3C=CC=CC=3)=CN=C2N1 KCKBBZRCPOVAQO-UHFFFAOYSA-N 0.000 description 1
- PIEOISUBEHIUKN-UHFFFAOYSA-N n-benzyl-2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-amine Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NCC=4C=CC=CC=4)C=C3C=2)=C1 PIEOISUBEHIUKN-UHFFFAOYSA-N 0.000 description 1
- NSYNDNYSQFKOGL-UHFFFAOYSA-N n-benzyl-2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-amine Chemical compound C=1C=CC=CC=1CNC(C=C1C=2)=CN=C1NC=2C1=CC=CC=C1 NSYNDNYSQFKOGL-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- KPMKNHGAPDCYLP-UHFFFAOYSA-N nimustine hydrochloride Chemical compound Cl.CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 KPMKNHGAPDCYLP-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 230000005853 oncogenic activation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002669 organ and tissue protective effect Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 229940045681 other alkylating agent in atc Drugs 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 229940069510 parthenolide Drugs 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- KKJMVRNMMPYWLH-UHFFFAOYSA-N pentan-3-yl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OC(CC)CC)=CN=C2NC=1C1=CC=CC=C1 KKJMVRNMMPYWLH-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000010469 pro-virus integration Effects 0.000 description 1
- ZWSLWXHQASYSJQ-UHFFFAOYSA-N propan-2-yl n-(2-thiophen-2-yl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=CS1 ZWSLWXHQASYSJQ-UHFFFAOYSA-N 0.000 description 1
- YBWGDZPMCBLJLW-UHFFFAOYSA-N propan-2-yl n-(2-thiophen-3-yl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C=1C=CSC=1 YBWGDZPMCBLJLW-UHFFFAOYSA-N 0.000 description 1
- IGMGBSKFRSHZSV-UHFFFAOYSA-N propan-2-yl n-[2-(2-methylpyridin-4-yl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=NC(C)=C1 IGMGBSKFRSHZSV-UHFFFAOYSA-N 0.000 description 1
- NDDHZDNWAMRGTQ-UHFFFAOYSA-N propan-2-yl n-[2-(3,4-difluorophenyl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=C(F)C(F)=C1 NDDHZDNWAMRGTQ-UHFFFAOYSA-N 0.000 description 1
- JFTGOZBNFKYGNK-UHFFFAOYSA-N propan-2-yl n-[2-(3-acetamidophenyl)-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound C=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=CC(NC(C)=O)=C1 JFTGOZBNFKYGNK-UHFFFAOYSA-N 0.000 description 1
- GEUYFTINDSXRPV-UHFFFAOYSA-N propan-2-yl n-[2-(3-methylsulfonylphenyl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=CC(S(C)(=O)=O)=C1 GEUYFTINDSXRPV-UHFFFAOYSA-N 0.000 description 1
- HFAGPDUYAYGKEE-UHFFFAOYSA-N propan-2-yl n-[2-(3-nitrophenyl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=CC([N+]([O-])=O)=C1 HFAGPDUYAYGKEE-UHFFFAOYSA-N 0.000 description 1
- UJEZMWPSFYQDQH-UHFFFAOYSA-N propan-2-yl n-[2-(4-aminophenyl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=C(N)C=C1 UJEZMWPSFYQDQH-UHFFFAOYSA-N 0.000 description 1
- NUXDUFNFLCZNKQ-UHFFFAOYSA-N propan-2-yl n-[2-(4-methylsulfanylphenyl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound C1=CC(SC)=CC=C1C1=NC2=CC(NC(=O)OC(C)C)=CN=C2N1 NUXDUFNFLCZNKQ-UHFFFAOYSA-N 0.000 description 1
- HSNRLRXLOLTEIB-UHFFFAOYSA-N propan-2-yl n-[2-(4-methylsulfinylphenyl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=C(S(C)=O)C=C1 HSNRLRXLOLTEIB-UHFFFAOYSA-N 0.000 description 1
- QYJAOSOKIMOHNL-UHFFFAOYSA-N propan-2-yl n-[2-(4-sulfamoylphenyl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=C(S(N)(=O)=O)C=C1 QYJAOSOKIMOHNL-UHFFFAOYSA-N 0.000 description 1
- ZCAJHZWDJTYJJV-UHFFFAOYSA-N propan-2-yl n-[2-[3-(2-hydroxyethyl)phenyl]-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=CC(CCO)=C1 ZCAJHZWDJTYJJV-UHFFFAOYSA-N 0.000 description 1
- RIXPNCHZCXAFDN-UHFFFAOYSA-N propan-2-yl n-[2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NC(=O)OC(C)C)C=C3C=2)=C1 RIXPNCHZCXAFDN-UHFFFAOYSA-N 0.000 description 1
- IPVCEVOAHAKGNG-UHFFFAOYSA-N propan-2-yl n-[2-[3-(3-methoxypropanoylamino)phenyl]-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound COCCC(=O)NC1=CC=CC(C=2NC3=NC=C(NC(=O)OC(C)C)C=C3N=2)=C1 IPVCEVOAHAKGNG-UHFFFAOYSA-N 0.000 description 1
- QUBRRMQOMGHQNT-UHFFFAOYSA-N propan-2-yl n-[2-[3-(3-methoxypropylcarbamoyl)phenyl]-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound COCCCNC(=O)C1=CC=CC(C=2NC3=NC=C(NC(=O)OC(C)C)C=C3N=2)=C1 QUBRRMQOMGHQNT-UHFFFAOYSA-N 0.000 description 1
- ASLQWRYCHAULHA-UHFFFAOYSA-N propan-2-yl n-[2-[4-(2-methoxyethoxy)phenyl]-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound C1=CC(OCCOC)=CC=C1C1=NC2=CC(NC(=O)OC(C)C)=CN=C2N1 ASLQWRYCHAULHA-UHFFFAOYSA-N 0.000 description 1
- JCPUGDMRRJXEBU-UHFFFAOYSA-N propan-2-yl n-[2-[4-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound C1=CC(OCCOC)=CC=C1C1=CC2=CC(NC(=O)OC(C)C)=CN=C2N1 JCPUGDMRRJXEBU-UHFFFAOYSA-N 0.000 description 1
- XMXFBMYALLFRBV-UHFFFAOYSA-N propan-2-yl n-[2-[4-(4-methylpiperazin-1-yl)phenyl]-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C(C=C1)=CC=C1N1CCN(C)CC1 XMXFBMYALLFRBV-UHFFFAOYSA-N 0.000 description 1
- NRKCJZSZGQUOPU-UHFFFAOYSA-N propan-2-yl n-[2-[4-[bis(2-methoxyethyl)amino]-3-fluorophenyl]-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound C1=C(F)C(N(CCOC)CCOC)=CC=C1C1=NC2=CC(NC(=O)OC(C)C)=CN=C2N1 NRKCJZSZGQUOPU-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- SBGILJXZHNBPTD-UHFFFAOYSA-N propyl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N1C2=CC(NC(=O)OCCC)=CN=C2N=C1C1=CC=CC=C1 SBGILJXZHNBPTD-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 1
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 1
- FVLAYJRLBLHIPV-UHFFFAOYSA-N pyrimidin-5-amine Chemical compound NC1=CN=CN=C1 FVLAYJRLBLHIPV-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- VSGPVHSTVTXREH-UHFFFAOYSA-N quinolin-4-one Chemical compound C1=CC=C[C]2C(=O)C=CN=C21 VSGPVHSTVTXREH-UHFFFAOYSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000002534 radiation-sensitizing agent Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000009834 selective interaction Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
- ZGVSETXHNHBTRK-OTYSSXIJSA-N solanine Chemical compound O([C@H]1[C@@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@@H]5N6C[C@@H](C)CC[C@@H]6[C@H]([C@@H]5[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZGVSETXHNHBTRK-OTYSSXIJSA-N 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940061353 temodar Drugs 0.000 description 1
- IGRFODZQTWGJMN-UHFFFAOYSA-N tert-butyl 4-[2-[4-(1-ethylpiperidin-4-yl)oxyanilino]thieno[3,2-d]pyrimidin-7-yl]pyrazole-1-carboxylate Chemical compound C1CN(CC)CCC1OC(C=C1)=CC=C1NC1=NC=C(SC=C2C3=CN(N=C3)C(=O)OC(C)(C)C)C2=N1 IGRFODZQTWGJMN-UHFFFAOYSA-N 0.000 description 1
- ATIFLMKJSCCIOR-UHFFFAOYSA-N tert-butyl 4-[2-[4-(morpholin-4-ylmethyl)anilino]thieno[3,2-d]pyrimidin-7-yl]-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(C=2C3=NC(NC=4C=CC(CN5CCOCC5)=CC=4)=NC=C3SC=2)=C1 ATIFLMKJSCCIOR-UHFFFAOYSA-N 0.000 description 1
- LSWNTXDGHBGOBU-UHFFFAOYSA-N tert-butyl 4-[2-[4-(morpholin-4-ylmethyl)anilino]thieno[3,2-d]pyrimidin-7-yl]pyrazole-1-carboxylate Chemical compound C1=NN(C(=O)OC(C)(C)C)C=C1C(C1=N2)=CSC1=CN=C2NC(C=C1)=CC=C1CN1CCOCC1 LSWNTXDGHBGOBU-UHFFFAOYSA-N 0.000 description 1
- JRQXEMLSEVXCRI-UHFFFAOYSA-N tert-butyl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)(C)C)=CN=C2NC=1C1=CC=CC=C1 JRQXEMLSEVXCRI-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 108091005990 tyrosine-phosphorylated proteins Proteins 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 238000010451 viral insertion Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664279P | 2012-06-26 | 2012-06-26 | |
| US61/664,279 | 2012-06-26 | ||
| US201361824672P | 2013-05-17 | 2013-05-17 | |
| US61/824,672 | 2013-05-17 | ||
| PCT/US2013/047320 WO2014004376A2 (en) | 2012-06-26 | 2013-06-24 | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018007222A Division JP2018087205A (ja) | 2012-06-26 | 2018-01-19 | ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015526410A JP2015526410A (ja) | 2015-09-10 |
| JP2015526410A5 JP2015526410A5 (enExample) | 2016-08-12 |
| JP6280546B2 true JP6280546B2 (ja) | 2018-02-14 |
Family
ID=49783991
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015520365A Expired - Fee Related JP6280546B2 (ja) | 2012-06-26 | 2013-06-24 | ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法 |
| JP2018007222A Pending JP2018087205A (ja) | 2012-06-26 | 2018-01-19 | ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018007222A Pending JP2018087205A (ja) | 2012-06-26 | 2018-01-19 | ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20150182490A1 (enExample) |
| EP (1) | EP2872161B1 (enExample) |
| JP (2) | JP6280546B2 (enExample) |
| KR (2) | KR102427777B1 (enExample) |
| CN (2) | CN112755193A (enExample) |
| AU (2) | AU2013280644B2 (enExample) |
| BR (1) | BR112014032346A2 (enExample) |
| CA (1) | CA2880896C (enExample) |
| CL (1) | CL2014003526A1 (enExample) |
| IL (1) | IL236470B (enExample) |
| MX (1) | MX367055B (enExample) |
| SG (3) | SG10201805807PA (enExample) |
| WO (1) | WO2014004376A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX380504B (es) | 2010-06-03 | 2025-03-12 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| HK1206073A1 (en) | 2012-07-24 | 2015-12-31 | 药品循环有限责任公司 | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| HK1220626A1 (zh) | 2013-03-15 | 2017-05-12 | The Centre For Drug Research And Development | 具细胞毒性和抗有丝分裂的化合物以及其使用方法 |
| WO2014179528A2 (en) * | 2013-05-01 | 2014-11-06 | Brown Dennis M | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions |
| MX2016008448A (es) | 2013-12-27 | 2017-01-09 | Zymeworks Inc | Conjugados de var2csa-farmaco. |
| KR102384740B1 (ko) | 2013-12-27 | 2022-04-07 | 자임워크스 인코포레이티드 | 약물 접합체를 위한 설폰아마이드-함유 연결 시스템 |
| US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
| KR102359214B1 (ko) * | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| MX2017001656A (es) | 2014-08-08 | 2017-07-24 | Pharmacyclics Llc | Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas. |
| ES2905569T3 (es) | 2014-09-17 | 2022-04-11 | Zymeworks Inc | Compuestos citotóxicos y antimitóticos y métodos para utilizarlos |
| CN108024987A (zh) * | 2014-10-10 | 2018-05-11 | 德玛医药 | 用于治疗癌症的二去水卫矛醇的类似物或衍生物与含铂抗肿瘤药物的组合 |
| WO2016059590A1 (en) * | 2014-10-16 | 2016-04-21 | Piramal Enterprises Limited | Stable injectable composition of small molecule drugs and process for its preparation |
| EP3328839A1 (en) * | 2015-07-30 | 2018-06-06 | Bristol-Myers Squibb Company | Aryl substituted bicyclic heteroaryl compounds |
| EP3355871A1 (en) * | 2015-10-02 | 2018-08-08 | Gilead Sciences, Inc. | Combinations of the btk inhibitor gs-4059 with inhibitors selected from a jak, ask1, brd and/or mmp9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases |
| WO2017075052A1 (en) * | 2015-10-28 | 2017-05-04 | Delmar Pharmaceuticals, Inc. | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies |
| CN105476996B (zh) * | 2015-12-21 | 2017-12-26 | 神威药业集团有限公司 | 姜黄素与阿法替尼联合治疗非小细胞肺癌的用途 |
| CN105663028B (zh) * | 2016-02-23 | 2018-10-30 | 广西梧州制药（集团）股份有限公司 | 一种含去水卫矛醇的经直肠给药双层缓释栓剂 |
| CN105663075B (zh) * | 2016-02-23 | 2018-09-14 | 广西梧州制药（集团）股份有限公司 | 一种二溴卫矛醇肠溶片及其制备方法 |
| US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
| TWI771344B (zh) | 2016-12-01 | 2022-07-21 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種ｖｅｇｆｒ抑制劑與ｐａｒｐ抑制劑聯合在製備治療胃癌的藥物中的用途 |
| ES2971286T3 (es) * | 2016-12-01 | 2024-06-04 | Oxford BioDynamics PLC | Aplicación de interacciones cromosómicas epigenéticas en diagnóstico de cáncer |
| SI3592355T1 (sl) | 2017-03-10 | 2026-04-30 | Atnx Spv, Llc | KX2-391/KX-01 za uporabo pri zdravljenju aktinične keratoze |
| US20200031920A1 (en) * | 2017-04-04 | 2020-01-30 | The George Washington University | Combination Therapy for Treating Cancer |
| MX2020005659A (es) | 2017-12-06 | 2020-08-20 | Jiangsu Hengrui Medicine Co | Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia. |
| KR20190106315A (ko) * | 2018-03-08 | 2019-09-18 | 고려대학교 산학협력단 | 비소세포폐암의 표피성장인자 수용체 표적 항암제에 대한 민감성 증진용 조성물 |
| CN112135825A (zh) | 2018-03-13 | 2020-12-25 | 夏尔人类遗传性治疗公司 | 血浆激肽释放酶抑制剂及其用途 |
| CN108653293B (zh) * | 2018-05-29 | 2020-08-11 | 复旦大学 | Jak2抑制剂在预防和治疗印戒细胞癌中的应用 |
| WO2020200291A1 (en) * | 2019-04-02 | 2020-10-08 | Cullgen (Shanghai) , Inc. | Compounds and methods of treating cancers |
| WO2020223229A1 (en) | 2019-04-29 | 2020-11-05 | Ribon Therapeutics, Inc. | Solid forms of a parp7 inhibitor |
| WO2021055589A1 (en) | 2019-09-18 | 2021-03-25 | Shire Human Genetic Therapies, Inc. | Heteroaryl plasma kallikrein inhibitors |
| CN114728962B (zh) | 2019-09-18 | 2025-09-19 | 武田药品工业有限公司 | 血浆激肽释放酶抑制剂及其用途 |
| TWI902715B (zh) | 2019-10-30 | 2025-11-01 | 美商律幫治療股份有限公司 | 作為ｐａｒｐ７抑制劑的嗒酮 |
| EP4054585A1 (en) | 2019-11-05 | 2022-09-14 | Abbvie Inc. | Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax |
| CN115916779B (zh) * | 2020-05-11 | 2025-09-16 | 克立弗治疗学股份有限公司 | 用于治疗癌症的VCP/p97抑制剂 |
| CN111863159B (zh) * | 2020-06-01 | 2022-02-25 | 中山大学孙逸仙纪念医院 | 一种肿瘤免疫治疗疗效预测的列线图模型的建立方法 |
| GB202013466D0 (en) * | 2020-08-27 | 2020-10-14 | Inst De Medicina Molecular Joaeo Lobo Antunes | Genetic construct |
| JP2024502990A (ja) * | 2021-01-06 | 2024-01-24 | インカーダ セラピューティクス， インコーポレイテッド | 吸入可能なイマチニブ製剤 |
| US20240199613A1 (en) * | 2021-03-17 | 2024-06-20 | Takeda Pharmaceutical Company Limited | Polycyclic inhibitors of plasma kallikrein |
| CN115745975B (zh) * | 2022-09-15 | 2023-11-24 | 中国药科大学 | 一种jak激酶结构域和假激酶结构域共抑制前药、制备方法及医药用途 |
| US20240307373A1 (en) * | 2023-03-17 | 2024-09-19 | Escend Pharmaceuticals, Inc. | Methods of use and compositions of bisbenzylisoquinolines for the treatment of malignancies |
| CN116987362B (zh) * | 2023-09-27 | 2023-12-05 | 常州宏巨电子科技有限公司 | 一种苯并噁嗪树脂基石墨烯薄膜材料及其制备方法和应用 |
| CN117405894B (zh) * | 2023-11-03 | 2025-02-18 | 华中科技大学同济医学院附属协和医院 | 蛋白激酶ck2在预测kras突变肺癌免疫治疗疗效中的新应用 |
Family Cites Families (222)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59186924A (ja) | 1983-04-08 | 1984-10-23 | Kureha Chem Ind Co Ltd | ヒト免疫グロブリン結合抗腫瘍剤 |
| US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
| US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
| US5484612A (en) | 1993-09-22 | 1996-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin |
| US6011069A (en) | 1995-12-26 | 2000-01-04 | Nisshin Flour Milling Co., Ltd. | Multidrug resistance inhibitors |
| US20020077461A1 (en) | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
| DK0923941T3 (da) | 1996-06-27 | 2006-09-18 | Chugai Pharmaceutical Co Ltd | Midler mod myelom der skal anvendes sammen med nitrogensennepantitumormidler |
| US6121245A (en) | 1997-01-29 | 2000-09-19 | Firshein; Richard N. | Method of treating cancer using alkylglycerols in conjunction with chemotherapy |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| US20040072889A1 (en) | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
| KR20010020611A (ko) | 1997-07-01 | 2001-03-15 | 아테로제닉스, 인코포레이티드 | 항산화제에 의한 과증식질병 치료의 향상 |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6100254A (en) | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
| WO1999063929A2 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
| JP2002520282A (ja) | 1998-07-09 | 2002-07-09 | フランシス エイ． ナーデラ， | 慢性リンパ性白血病の処置のための方法および組成物 |
| ES2342240T3 (es) | 1998-08-11 | 2010-07-02 | Novartis Ag | Derivados de isoquinolina con actividad que inhibe la angiogenia. |
| US6326390B1 (en) | 1998-08-25 | 2001-12-04 | King Pharmaceuticals Reseach And Development, Inc. | Use of adenosine A3 receptor antagonists to inhibit tumor growth |
| ATE329596T1 (de) | 1999-03-30 | 2006-07-15 | Novartis Pharma Gmbh | Phthalazinderivate zur behandlung von entzündlicher erkrankungen |
| US8791081B2 (en) | 1999-08-13 | 2014-07-29 | Case Western Reserve University | MGMT inhibitor combination for the treatment of neoplastic disorders |
| US7811981B2 (en) | 1999-08-30 | 2010-10-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of and compositions for inhibiting the proliferation of mammalian cells |
| AR030557A1 (es) | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
| US6921722B2 (en) | 2000-05-30 | 2005-07-26 | Ebara Corporation | Coating, modification and etching of substrate surface with particle beam irradiation of the same |
| US20030072794A1 (en) | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
| US6613736B2 (en) | 2000-06-16 | 2003-09-02 | Thomas T. Aoki | System and method for treating eye and nerve diseases in diabetic and non-diabetic patients |
| CA2413313C (en) | 2000-06-23 | 2011-06-14 | Mitsubishi Pharma Corporation | Antitumor effect potentiators |
| AU2001290912A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| CN1116875C (zh) | 2000-10-19 | 2003-08-06 | 南京振中生物工程有限公司 | 紫杉醇脂质组合物及其制备方法 |
| US6503914B1 (en) | 2000-10-23 | 2003-01-07 | Board Of Regents, The University Of Texas System | Thienopyrimidine-based inhibitors of the Src family |
| AU2002227383B2 (en) | 2000-10-30 | 2004-07-08 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| US7619005B2 (en) | 2000-11-01 | 2009-11-17 | Cognition Pharmaceuticals Llc | Methods for treating cognitive impairment in humans with Multiple Sclerosis |
| US20020155565A1 (en) | 2000-11-10 | 2002-10-24 | Pilar Garin-Chesa | FAP-activated anti-tumor compounds |
| BR0116493A (pt) | 2000-12-21 | 2003-09-30 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
| US20100098691A1 (en) | 2001-01-24 | 2010-04-22 | S'bio Pte Ltd | Combination of benzimidazole anti-cancer agent and a second anti-cancer agent |
| PT1397155E (pt) | 2001-06-21 | 2015-12-07 | Genentech Inc | Formulação de libertação sustentada |
| US7005445B2 (en) | 2001-10-22 | 2006-02-28 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors and methods for designing them |
| US20030158118A1 (en) | 2001-11-26 | 2003-08-21 | Weidner Morten Sloth | Combination of cimetidine and cysteine derivatives for treating cancer |
| UA76810C2 (uk) | 2001-12-10 | 2006-09-15 | Мерк Енд Ко., Інк. | Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок |
| US7045534B2 (en) | 2002-02-12 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of reducing angiogenesis |
| WO2003070823A2 (en) | 2002-02-20 | 2003-08-28 | The General Hospital Corporation | Conjugates comprising a biodegradable polymer and uses therefor |
| US7101576B2 (en) | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
| US7262200B2 (en) | 2002-10-25 | 2007-08-28 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| US7129351B2 (en) | 2002-11-04 | 2006-10-31 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| TW200413381A (en) | 2002-11-04 | 2004-08-01 | Hoffmann La Roche | Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents |
| EP2305813A3 (en) | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| CL2003002287A1 (es) | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| US7276519B2 (en) | 2002-11-25 | 2007-10-02 | Wyeth | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors |
| KR20050090435A (ko) | 2002-12-30 | 2005-09-13 | 셀진 코포레이션 | 플루오로알콕시-치환된 1,3-디히드로-이소인돌릴 화합물 및그의 제약학적 용도 |
| PT2476667E (pt) | 2003-02-26 | 2014-09-18 | Sugen Inc | Compostos de aminoheteroarilo como inibidores da proteína quinase |
| NZ543122A (en) | 2003-03-24 | 2008-07-31 | Sequoia Pharmaceuticals Inc | An HIV fusion inhibitor peptide covalently linked to a blood protein |
| TW200502236A (en) | 2003-03-28 | 2005-01-16 | Hoffmann La Roche | Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents |
| US7220706B1 (en) | 2003-05-14 | 2007-05-22 | Praxair S.T. Technology, Inc. | Enhanced melt-textured growth |
| US7385055B2 (en) | 2003-05-19 | 2008-06-10 | Board Of Trustees Of Michigan State University | Preparation of hymenialdisine derivatives and use thereof |
| US7842835B2 (en) | 2003-07-07 | 2010-11-30 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
| US20050009891A1 (en) | 2003-07-09 | 2005-01-13 | Lee Francis Y. | Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases |
| ATE455546T1 (de) | 2003-08-06 | 2010-02-15 | Vertex Pharma | Aminotriazol-verbindungen als proteinkinase- hemmer |
| RU2006106768A (ru) | 2003-08-07 | 2007-09-20 | Шеринг Корпорейшн (US) | Новые ингибиторы фарнезилпротеинтрансферазы как противоопухолевые агенты |
| TW200526668A (en) | 2003-10-02 | 2005-08-16 | Salmedix Inc | Substituted indole derivatives |
| HUP0303313A2 (hu) | 2003-10-09 | 2005-07-28 | Richter Gedeon Vegyészeti Gyár Rt. | Transzdermális gyógyszerkészítmények |
| US7169781B2 (en) | 2003-10-17 | 2007-01-30 | Hoffmann-La Roche Inc. | Imidazole derivatives and their use as pharmaceutical agents |
| CA2543163A1 (en) | 2003-11-06 | 2005-05-26 | Wyeth | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) |
| US7491725B2 (en) | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| WO2005080392A1 (ja) | 2004-02-19 | 2005-09-01 | Takeda Pharmaceutical Company Limited | ピラゾロキノロン誘導体およびその用途 |
| EP1727819A1 (en) | 2004-03-15 | 2006-12-06 | F.Hoffmann-La Roche Ag | Novel dichloro-phenyl-pyrido¬2,3-d|pyrimidine derivatives, their manufacture and use as pharmaceutical agents |
| WO2005092326A1 (en) | 2004-03-22 | 2005-10-06 | The Regents Of The University Of Michigan | Small molecule antagonists of xiap family proteins |
| CA2561617A1 (en) | 2004-04-05 | 2005-10-20 | Aton Pharma, Inc. | Histone deacetylase inhibitor prodrugs |
| TW200538149A (en) | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
| TW200600091A (en) | 2004-05-21 | 2006-01-01 | Telik Inc | Sulfonylethyl phosphorodiamidates |
| SI1771474T1 (sl) | 2004-07-20 | 2010-06-30 | Genentech Inc | Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba |
| SE0402025D0 (sv) | 2004-08-13 | 2004-08-13 | Active Biotech Ab | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
| US7479561B2 (en) | 2004-08-16 | 2009-01-20 | Wyeth | 4-(2,4-dichloro-5-methoxyphenyl)amino-6-methoxy-7-{[5-substituted-amino)methyl]-3-furyl}-3-quinolinecarbonitriles as kinase inhibitors |
| EP1789417A1 (en) | 2004-08-31 | 2007-05-30 | F.Hoffmann-La Roche Ag | AMIDE DERIVATIVES OF 7-AMINO-3-PHENYL-DIHYDROPYRIMIDO [4,5-d]PYRIMIDINONES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS |
| US20060100226A1 (en) | 2004-09-10 | 2006-05-11 | Sikorski James A | 2-Thiopyrimidinones as therapeutic agents |
| WO2006032452A1 (en) | 2004-09-21 | 2006-03-30 | F. Hoffmann-La Roche Ag | 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as proteine kinase inhibitors |
| US7355677B2 (en) | 2004-12-09 | 2008-04-08 | Asml Netherlands B.V. | System and method for an improved illumination system in a lithographic apparatus |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| EP1833829A2 (en) | 2004-12-23 | 2007-09-19 | F. Hoffmann-Roche AG | Benzamide substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
| CA2589877A1 (en) | 2004-12-23 | 2006-06-29 | F. Hoffmann-La Roche Ag | Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
| US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| NZ560712A (en) | 2005-02-17 | 2010-12-24 | Synta Pharmaceuticals Corp | (3,4,5-trisubstituted-phenyl)isoxazole combretastin derivatives for the treatment of disorders |
| US20060229277A1 (en) | 2005-04-08 | 2006-10-12 | Orbus Pharma, Inc. | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor |
| US8242103B2 (en) | 2005-05-19 | 2012-08-14 | Merck Sharp & Dohme Limited | Sulphamides for treatment of cancer |
| BRPI0613796A2 (pt) | 2005-06-07 | 2011-02-15 | Univ Yale | composicões farmacêuticas e seus usos, e métodos de tratamento de cáncer e outras condições ou estados patológicos, por meio do uso de clevudina (lfmau) e telbivudina (ldt) |
| JP5159616B2 (ja) | 2005-06-15 | 2013-03-06 | カーディオム ファーマ コーポレイション | アミノシクロヘキシルエーテル化合物の調製のための合成プロセス |
| RU2408584C2 (ru) | 2005-06-23 | 2011-01-10 | Мерк Шарп Энд Домэ Корп. | Ингибиторы тирозинкиназы |
| HUE035853T2 (en) | 2005-07-18 | 2018-05-28 | Seattle Genetics Inc | Beta-glucuronide-linker-drug conjugates |
| EP1912987A1 (en) | 2005-08-01 | 2008-04-23 | F. Hoffmann-Roche AG | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents |
| CA2621983A1 (en) | 2005-09-09 | 2007-03-22 | Schering Corporation | Azafused cyclin dependent kinase inhibitors |
| EA015781B1 (ru) | 2005-10-21 | 2011-12-30 | Панацея Биотек Лимитед | Композиции для лечения рака |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| JP5249770B2 (ja) | 2005-11-03 | 2013-07-31 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼインヒビターとして有用なアミノピリジン |
| WO2007065559A1 (en) | 2005-11-18 | 2007-06-14 | Synthon B.V. | Zolpidem tablets |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| US8014957B2 (en) * | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| WO2007081751A2 (en) | 2006-01-05 | 2007-07-19 | The Johns Hopkins University | Compositions and methods for the treatment of cancer |
| EP1981886B1 (en) | 2006-01-31 | 2009-08-12 | F.Hoffmann-La Roche Ag | 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors |
| WO2007106555A2 (en) | 2006-03-14 | 2007-09-20 | Neuren Pharmaceuticals Limited | Oral formulations of glycyl-2-methylprolyl-glutamate |
| CA2644369A1 (en) | 2006-03-28 | 2007-10-04 | Novartis Ag | Amide derivatives and their application for the treatment of g protein related diseases |
| CA2645633A1 (en) | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| WO2007127137A2 (en) | 2006-04-26 | 2007-11-08 | Merck & Co., Inc. | Disubstituted aniline compounds |
| US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
| GB0609378D0 (en) | 2006-05-11 | 2006-06-21 | Novartis Ag | Organic compounds |
| US7964728B2 (en) | 2006-07-06 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition |
| TW200813021A (en) | 2006-07-10 | 2008-03-16 | Merck & Co Inc | Tyrosine kinase inhibitors |
| JP2009543823A (ja) | 2006-07-17 | 2009-12-10 | ノバルティス アクチエンゲゼルシャフト | 免疫調節剤として使用するための胆汁酸アミドのスルホニルアミノカルボニル誘導体 |
| US8080252B2 (en) | 2006-07-19 | 2011-12-20 | The Cleveland Clinic Foundation | Compounds and methods of modulating angiogenesis |
| MX2009000824A (es) | 2006-07-24 | 2009-02-04 | Tetralogic Pharmaceuticals Cor | Antagonistas dimericos de las proteinas inhibidoras de la apoptosis. |
| US7683060B2 (en) | 2006-08-07 | 2010-03-23 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
| AU2007281682B2 (en) | 2006-08-07 | 2013-05-16 | Abbvie Biotherapeutics Inc. | Compositions and methods using anti-CS1 antibodies to treat multiple myeloma |
| CA2659425C (en) | 2006-08-17 | 2017-06-20 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| CN101501051A (zh) | 2006-08-23 | 2009-08-05 | 诺瓦提斯公司 | 作为神经磷脂酶抑制剂的酰胺化合物 |
| US8222288B2 (en) | 2006-08-30 | 2012-07-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| DK2061765T3 (en) | 2006-09-01 | 2015-01-26 | Senhwa Biosciences Inc | Serine-threonine protein kinase AND PARP-MODULATOR |
| WO2008030883A2 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
| WO2008030408A2 (en) | 2006-09-05 | 2008-03-13 | Yale University | Proteomimetic compounds as inhibitors of the interaction of a nuclear receptor with coactivator peptides |
| US8242080B2 (en) | 2006-10-13 | 2012-08-14 | The Regents Of The University Of California | Inhibitors of the EGFR kinase targeting the asymmetric activating dimer interface |
| US8283441B2 (en) | 2006-10-31 | 2012-10-09 | University Of Toledo | Na+K+-ATPase-specific peptide inhibitors/activators of SRC and SRC family kinases |
| US8227605B2 (en) | 2006-10-31 | 2012-07-24 | Schering Corporation | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
| US7750007B2 (en) | 2006-11-06 | 2010-07-06 | Supergen, Inc. | Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors |
| US20120164075A1 (en) | 2006-11-21 | 2012-06-28 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of mammalian diseases |
| US20080125397A1 (en) | 2006-11-28 | 2008-05-29 | Telik, Inc. | 2 (SULFONYL)ETHYL N,N,N',N' tetrakis(2 chloroethyl)phosphorodia |
| US7655799B2 (en) | 2006-11-29 | 2010-02-02 | Telik, Inc. | 2{[2-(substituted amino)ethyl]sulfonyl}ethyl N,N,N',N'-tetrakis(2-chloroethyl)phosphorodiamidates |
| US7776917B2 (en) | 2006-12-11 | 2010-08-17 | Mickle Travis C | Non-standard amino acid conjugates of amphetamine and processes for making and using the same |
| EP1932820A1 (en) | 2006-12-14 | 2008-06-18 | Bp Oil International Limited | Process for manufacturing neohexene |
| US7956216B2 (en) | 2006-12-21 | 2011-06-07 | The Walter And Eliza Hall Institute Of Medical Research | Alpha-helical mimetics |
| WO2008079982A2 (en) | 2006-12-21 | 2008-07-03 | Centocor, Inc. | Liposome composition for targeting egfr receptor |
| WO2008079973A2 (en) | 2006-12-21 | 2008-07-03 | Centocor, Inc. | Egfr binding peptides and uses thereof |
| US20080293648A1 (en) | 2007-01-05 | 2008-11-27 | Saha Pharmaceuticals, Inc. | Compositions and Methods for Cancer Treatment |
| MX2009008425A (es) | 2007-02-06 | 2009-08-17 | Novartis Ag | Derivados de 1-bencensulfonil-1h-indol como inhibidores de la actividad de ccr9. |
| CA2677651A1 (en) | 2007-02-15 | 2008-08-21 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| JP5383513B2 (ja) | 2007-03-09 | 2014-01-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 化合物およびその標的に関連する組成物ならびに方法 |
| US8501233B2 (en) | 2007-03-13 | 2013-08-06 | Wake Forest University | Compositions and methods for treating cancer |
| PT2139484E (pt) | 2007-04-10 | 2013-10-31 | Exelixis Inc | Métodos de tratamento de cancro usando inibidores piridopirimidinona de pi3k-alfa |
| US20100048579A1 (en) | 2007-04-13 | 2010-02-25 | Luca Arista | Pyridazine-, pyridine- and pyrane-derivatives as gpbar1 agonists |
| TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
| US7838495B2 (en) | 2007-04-27 | 2010-11-23 | University Of Maryland, Baltimore | Compositions and methods of use of EPB1, and ErbB3 binding protein |
| WO2008137619A2 (en) | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
| WO2008144506A1 (en) | 2007-05-16 | 2008-11-27 | University Of Maryland, Baltimore | Apoptotic pathway targeting for the diagnosis and treatment of cancer |
| US8367078B2 (en) | 2007-06-06 | 2013-02-05 | University Of Florida Research Foundation, Inc. | Kinase inhibitor compounds |
| US20110288023A1 (en) | 2007-06-08 | 2011-11-24 | The Regents Of The University Of California Office Of Technology Transfer | Cancer drug delivery using modified transferrin |
| WO2009003911A1 (en) | 2007-06-29 | 2009-01-08 | 4Sc Ag | Thiophene-imidazopyridines |
| WO2009008992A2 (en) | 2007-07-06 | 2009-01-15 | Osi Pharmaceuticals Inc. | Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2 |
| EP2545938A1 (en) | 2007-08-03 | 2013-01-16 | Abbott Biotherapeutics Corp. | Therapeutic use of anti-tweak receptor antibodies |
| EP2190429B1 (en) | 2007-09-10 | 2016-04-20 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
| US20100311678A1 (en) | 2007-10-04 | 2010-12-09 | Bean Bruce P | Methods and compositions for treating cancer and modulating signal transduction and metabolism pathways |
| CN101903403B (zh) | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| JP2011500806A (ja) | 2007-10-25 | 2011-01-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
| SI2215094T1 (sl) | 2007-11-15 | 2016-05-31 | Ym Biosciences Australia Pty Ltd | N vsebujoče heterociklične spojine |
| JP5758630B2 (ja) | 2007-11-15 | 2015-08-05 | エンメエッセディ・イタリア・エッセ・エッレ・エッレ | Ｐａｒｐ阻害剤としてのピリダジノン誘導体 |
| EA020777B1 (ru) | 2007-11-16 | 2015-01-30 | Инсайт Корпорейшн | 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus |
| CN101444490A (zh) | 2007-11-26 | 2009-06-03 | 天津市金圭谷木糖醇有限公司 | 一种含脱水卫矛醇经注射给药的制剂及其制备方法 |
| CN101450100A (zh) | 2007-11-28 | 2009-06-10 | 天津金世制药有限公司 | 一种治疗急慢性粒细胞白血病的药物组合物 |
| WO2009076629A2 (en) | 2007-12-12 | 2009-06-18 | The Regents Of The University Of Michigan | Compositions and methods for treating cancer |
| EP2240172B1 (en) | 2007-12-21 | 2014-03-19 | Novartis AG | Combination of nilotinib and chlorambucil for the treatment of chronic lymphocytic leukemia |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| BRPI0907754A2 (pt) * | 2008-02-08 | 2015-07-21 | Aileron Therapeutics Inc | Macrociclos peptidomiméticos terapêuticos |
| US20090202540A1 (en) | 2008-02-11 | 2009-08-13 | Auspex Pharmaceuticals, Inc. | Substituted oxazaphosphorines |
| US20090209340A1 (en) | 2008-02-14 | 2009-08-20 | Aruze Gaming America, Inc. | Gaming Apparatus Capable of Conversation with Player and Control Method Thereof |
| EP2259791A2 (en) | 2008-03-05 | 2010-12-15 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer |
| MY165582A (en) | 2008-03-11 | 2018-04-05 | Incyte Holdings Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| EP2110377A1 (en) | 2008-04-15 | 2009-10-21 | DAC S.r.l. | Spirocyclic derivatives as histone deacetylase inhibitors |
| NZ588884A (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Cross-linkers and their uses |
| US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US8207169B2 (en) | 2008-06-03 | 2012-06-26 | Msd K.K. | Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D |
| GB2475183B (en) | 2008-06-04 | 2011-11-23 | Gw Pharma Ltd | Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators |
| EP2133334A1 (en) | 2008-06-09 | 2009-12-16 | DAC S.r.l. | Heterocyclic derivatives as HDAC inhibitors |
| ES2531322T3 (es) * | 2008-06-17 | 2015-03-13 | Wyeth Llc | Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina |
| US8207195B2 (en) | 2008-06-26 | 2012-06-26 | Inspire Pharmaceuticals, Inc. | Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds |
| CA3012229C (en) | 2008-07-08 | 2020-11-10 | Incyte Holdings Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| US8217076B2 (en) | 2008-07-17 | 2012-07-10 | Colorado State University Research Foundation | Method for preparing largazole analogs and uses thereof |
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| WO2010014755A1 (en) | 2008-07-29 | 2010-02-04 | The Regents Of The University Of Colorado | Methods and compounds for enhancing anti-cancer therapy |
| WO2010021822A2 (en) | 2008-07-30 | 2010-02-25 | The Regents Of The University Of California | Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites |
| CA2732437C (en) | 2008-08-01 | 2017-11-21 | Ventirx Pharmaceuticals, Inc. | Toll-like receptor agonist formulations and their use |
| BRPI0918971A2 (pt) | 2008-08-26 | 2015-12-01 | Boehringer Ingelheim Int | tienopirimidinas para composições farmacêuticas |
| US20100068302A1 (en) | 2008-09-17 | 2010-03-18 | Traslational Cancer Drugs Pharma, S.L. | Methods and compositions for the treatment of cancer |
| US20100111901A1 (en) | 2008-11-03 | 2010-05-06 | Auspex Pharmaceuticals, Inc. | Triazole inhibitors of aromatase |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| RU2016116516A (ru) | 2008-12-08 | 2018-12-07 | Мандифарма Интернэшнл Корпорейшн Лимитед | Композиции ингибиторов тирозинкиназных рецепторов белков |
| WO2010068920A2 (en) | 2008-12-12 | 2010-06-17 | Auspex Pharmaceutical, Inc. | Diaminoquinazoline inhibitors of dihydrofolate reductase |
| PA8851101A1 (es) | 2008-12-16 | 2010-07-27 | Lilly Co Eli | Compuesto amino pirazol |
| WO2010080570A2 (en) | 2008-12-18 | 2010-07-15 | New York University | Tumor therapy with antitumor agents in combination with sindbis virus-based vectors |
| US20100173013A1 (en) | 2009-01-08 | 2010-07-08 | Denis Drygin | Treatment of neoplastic disorders using combination therapies |
| AR075239A1 (es) * | 2009-02-04 | 2011-03-16 | Bipar Sciences Inc | Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso |
| EP3620154A1 (en) | 2009-02-06 | 2020-03-11 | University Of Southern California | Therapeutic compositions comprising monoterpenes |
| AR075812A1 (es) | 2009-03-11 | 2011-04-27 | Plexxikon Inc | Derivados de pirrol[2,3-b]piridina como inhibidores de raf quinasa |
| BRPI1014854A2 (pt) | 2009-03-30 | 2016-05-03 | Cerulean Pharma Inc | "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados" |
| US8574829B2 (en) | 2009-03-31 | 2013-11-05 | The Trustees Of The University Of Pennsylvania | Methods of treating cancer with phenformin |
| WO2010114881A1 (en) | 2009-04-01 | 2010-10-07 | Progenra Inc. | Anti-neoplastic compounds, compositions and methods |
| JP5756457B2 (ja) | 2009-04-06 | 2015-07-29 | アジオス ファーマシューティカルズ， インコーポレイテッド | ピルビン酸キナーゼｍ２調節剤、治療組成物および関連する使用方法 |
| US20100291025A1 (en) | 2009-04-13 | 2010-11-18 | Auspex Pharmaceuticals, Inc. | Indazole inhibitors of tyrosine kinase |
| US20110053968A1 (en) | 2009-06-09 | 2011-03-03 | Auspex Pharmaceuticals, Inc. | Aminopyrimidine inhibitors of tyrosine kinase |
| WO2010144808A2 (en) | 2009-06-12 | 2010-12-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Identification of dsg-3 as a biomarker for the detection of metastasis in lymph nodes |
| US8232318B2 (en) | 2009-07-31 | 2012-07-31 | The General Hospital Corporation | Approaches to treat cancer using HB-EGF inhibitors |
| AR077974A1 (es) | 2009-08-28 | 2011-10-05 | Takeda Pharmaceutical | Compuestos de hexahidrooxazinopterina para uso como inhibidores de mtor |
| MX2012002994A (es) | 2009-09-11 | 2012-07-17 | Cylene Pharmaceuticals Inc | Lactamas heterociclo-substituidas farmaceuticamente utiles. |
| CN102647904A (zh) | 2009-09-16 | 2012-08-22 | 赛林药物股份有限公司 | 新型三环蛋白激酶调节剂 |
| TWI423980B (zh) | 2009-09-28 | 2014-01-21 | Hoffmann La Roche | 苯并氧氮呯ｐｉ３ｋ抑制劑化合物及使用方法 |
| US8304577B2 (en) | 2009-10-09 | 2012-11-06 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| CA2777043C (en) * | 2009-10-14 | 2015-12-15 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
| MY173390A (en) | 2009-10-23 | 2020-01-22 | Takeda Pharmaceuticals Co | Anti-gcc antibody molecules and related compositions and methods |
| PL2509602T3 (pl) | 2009-12-04 | 2017-08-31 | Senhwa Biosciences, Inc. | Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2 |
| US8445517B2 (en) | 2009-12-11 | 2013-05-21 | Dana-Farber Cancer Institute | Stat modulators |
| US20110195066A1 (en) | 2010-02-05 | 2011-08-11 | Auspex Pharmaceuticals, Inc. | Quinoline inhibitors of tyrosine kinase |
| AU2011218805A1 (en) | 2010-02-24 | 2012-08-30 | Auspex Pharmaceuticals, Inc. | Trimethoxyphenyl inhibitors of tyrosine kinase |
| ES2562959T3 (es) | 2010-02-26 | 2016-03-09 | Evotec International Gmbh | Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas |
| UY33241A (es) | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
| WO2011109799A1 (en) | 2010-03-05 | 2011-09-09 | Karyopharm Therapeutics, Inc. | Nuclear transport modulatiors and uses thereof |
| US8389525B2 (en) | 2010-05-05 | 2013-03-05 | Renee Desai | Small molecules for inhibition of protein kinases |
| US9096584B2 (en) | 2010-05-12 | 2015-08-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| RU2012154025A (ru) * | 2010-05-14 | 2014-06-20 | Дженентек, Инк. | Способы лечения |
| US8846707B2 (en) * | 2010-08-02 | 2014-09-30 | Univeristy Of Central Florida Research Foundation, Inc. | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat protein |
| BR112013003671A2 (pt) * | 2010-08-18 | 2017-01-10 | Del Mar Pharmaceuticals | composições e métodos para melhorar os benefícios terapêuticos de compostos químicos administyrados sub-otimamente incluindo hexitóis substituídos tais como dianidrogalactitol e diacetildianidrogalactiol |
| US9029103B2 (en) * | 2010-08-27 | 2015-05-12 | Illumina Cambridge Limited | Methods for sequencing polynucleotides |
| US20120213854A1 (en) | 2010-09-30 | 2012-08-23 | Fetzer Oliver S | Methods of treating a subject and related particles, polymers and compositions |
| WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| SG182016A1 (en) * | 2010-12-14 | 2012-07-30 | Univ Singapore | Method of detecting resistance to cancer therapy |
| WO2013142817A2 (en) * | 2012-03-23 | 2013-09-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| US9814693B2 (en) * | 2012-05-09 | 2017-11-14 | Delmar Pharmaceuticals, Inc. | Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies |
| US8729286B2 (en) * | 2012-05-10 | 2014-05-20 | Massachusetts Institute Of Technology | Platinum compounds as treatment for cancers, and related methods, kits, and compositions |
-
2013
- 2013-06-24 US US14/409,909 patent/US20150182490A1/en not_active Abandoned
- 2013-06-24 SG SG10201805807PA patent/SG10201805807PA/en unknown
- 2013-06-24 SG SG10201610869TA patent/SG10201610869TA/en unknown
- 2013-06-24 CN CN202110071253.8A patent/CN112755193A/zh active Pending
- 2013-06-24 WO PCT/US2013/047320 patent/WO2014004376A2/en not_active Ceased
- 2013-06-24 JP JP2015520365A patent/JP6280546B2/ja not_active Expired - Fee Related
- 2013-06-24 SG SG11201408679XA patent/SG11201408679XA/en unknown
- 2013-06-24 CN CN201380042796.0A patent/CN104797267A/zh active Pending
- 2013-06-24 MX MX2014015795A patent/MX367055B/es active IP Right Grant
- 2013-06-24 AU AU2013280644A patent/AU2013280644B2/en not_active Ceased
- 2013-06-24 CA CA2880896A patent/CA2880896C/en active Active
- 2013-06-24 EP EP13809749.8A patent/EP2872161B1/en active Active
- 2013-06-24 KR KR1020217036438A patent/KR102427777B1/ko not_active Expired - Fee Related
- 2013-06-24 BR BR112014032346A patent/BR112014032346A2/pt not_active Application Discontinuation
- 2013-06-24 KR KR20157002161A patent/KR20150034209A/ko not_active Ceased
-
2014
- 2014-12-24 CL CL2014003526A patent/CL2014003526A1/es unknown
- 2014-12-25 IL IL236470A patent/IL236470B/en active IP Right Grant
-
2018
- 2018-01-19 JP JP2018007222A patent/JP2018087205A/ja active Pending
- 2018-10-29 AU AU2018256477A patent/AU2018256477A1/en not_active Abandoned
-
2021
- 2021-02-17 US US17/177,665 patent/US20210251944A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN104797267A (zh) | 2015-07-22 |
| AU2013280644B2 (en) | 2018-08-02 |
| AU2018256477A1 (en) | 2018-11-22 |
| KR20210138132A (ko) | 2021-11-18 |
| IL236470B (en) | 2019-06-30 |
| SG11201408679XA (en) | 2015-01-29 |
| KR20150034209A (ko) | 2015-04-02 |
| CL2014003526A1 (es) | 2015-08-28 |
| SG10201805807PA (en) | 2018-08-30 |
| CN112755193A (zh) | 2021-05-07 |
| KR102427777B1 (ko) | 2022-08-01 |
| WO2014004376A3 (en) | 2014-03-27 |
| IL236470A0 (en) | 2015-02-26 |
| SG10201610869TA (en) | 2017-02-27 |
| WO2014004376A2 (en) | 2014-01-03 |
| BR112014032346A2 (pt) | 2017-06-27 |
| AU2013280644A1 (en) | 2015-01-22 |
| MX367055B (es) | 2019-08-02 |
| EP2872161B1 (en) | 2020-12-16 |
| CA2880896A1 (en) | 2014-01-03 |
| MX2014015795A (es) | 2015-10-14 |
| JP2015526410A (ja) | 2015-09-10 |
| CA2880896C (en) | 2021-11-16 |
| US20150182490A1 (en) | 2015-07-02 |
| JP2018087205A (ja) | 2018-06-07 |
| EP2872161A4 (en) | 2016-07-20 |
| US20210251944A1 (en) | 2021-08-19 |
| EP2872161A2 (en) | 2015-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210251944A1 (en) | Methods for treating a cancer resistant to at least one tyrosine kinase inhibitor | |
| AU2019283893B2 (en) | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | |
| US20200206188A1 (en) | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | |
| AU2024200650A1 (en) | Therapeutic benefit of suboptimally administered chemical compounds | |
| AU2016262079A1 (en) | Combination of analogs or derivatives of dianhydrogalactitol with platinum-containing antineoplastic agents to treat cancer | |
| US20190091195A1 (en) | Use of dianhydrogalactitol and derivatives thereof in the treatment of glioblastoma, lung cancer, and ovarian cancer | |
| US20180071244A1 (en) | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | |
| TW201444551A (zh) | 使用衛康醇、二乙醯二脫水衛矛醇、二溴衛矛醇或類似物或其衍生物治療具有基因多型性或ａｈｉ１失調或突變患者的抗酪氨酸激酶抑制劑之惡性腫瘤的方法 | |
| HK1224581A1 (en) | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brian tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160623 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160623 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170411 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170707 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170823 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171024 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171108 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171121 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171213 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180119 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6280546 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |